

Curriculum Vitae

LAWRENCE A POTEPA, PHD

Home address: Deerfield, IL USA

Mobile telephone: 847-220-0506

Email: lapotempa@outlook.com

EDUCATION

1977-1979	Rush, Presbyterian St. Luke's Medical Center, Chicago, IL 60612 Postdoctoral Research Fellow, Field of Immunology (Mentor: Dr. Henry Gewurz)
1973-1977	Northwestern University Feinberg School of Medicine, Chicago, IL 60611 Doctor of Philosophy, Field of Biochemistry (Mentor: Dr. James E. Garvin)
1969-1973	Bradley University, Peoria, IL 61625 Bachelor of Science, Field of Biology (Mentor: Dr. Alan G. Galsky)

EMPLOYMENT, ACADEMIC AND INDUSTRY AFFILIATIONS

June 2017-present	Chair Research and Scholarly Endeavors Roosevelt University School of Pharmacy Schaumburg, IL 60173
Aug 2021-present	Professor of Biochemistry and Immunology Roosevelt University School of Pharmacy College of Science, Health, and Pharmacy Schaumburg, IL 60173
Oct 2010-July 2021	Associate Professor of Biochemistry and Immunology Roosevelt University College/School of Pharmacy Schaumburg, IL 60173
June 2008-present	President, Chief Scientist, Founder Aphazin, Inc. Deerfield, IL 60015 (a virtual Biotechnology Co)
Sept 2003-May 2008	Vice President – Research; Chief Scientific Officer (9/03-12/06) Immtech Pharmaceuticals, Inc (Previously Immtech International) Vernon Hills, IL 60061
Oct 2006-Mar 2008	Consultant – Angiogen, LLC (a Biotechnology Co. developing anti-angiogenesis treatment therapy) Chicago, IL 60602 and Charlette, NC

Jan 2003-Sep 2003	Program Manager Immtech International, Inc. Vernon Hills, IL 60061
June-1998-July 2002	Scientific Founder, Vice President, Chief Scientific Officer NextEra Therapeutics, Inc Vernon Hills, IL and Columbus, OH
June 1998-Mar 2000	Director – NextEra Therapeutics, Inc. Vernon Hills, IL 60061
Mar 1998-Dec 1999	Consultant - ImmvaRx Inc. (a Biotechnology Co. developing cancer vaccines) Rockford, IL
Jan 1996- June 2000	Vice President - Research, Chief Scientific Officer Immtech International, Inc. Vernon Hills, IL 60061
Jan 1993-Dec 1995	Chief Scientific Officer - Director of Immunobiochemistry Immtech International, Inc. Evanston, IL 60201
Jan 1990-Dec 1992	Director of Immunology - Program Manager - Key Scientist Immtech International, Inc. Evanston, IL 60201
Mar 1989-Jun 1995	Adjunct Associate Professor Northwestern University Medical School Department of Medicine Chicago, IL 60611
Jan 1988-Jan 1990	Senior Research Scientist - Program Director – Immtech International, Inc. Evanston, IL 60201
Apr 1987-Dec 1997	Consultant to Immtech International, Inc. Evanston, IL & Milwaukee, WI
July 1979-Dec 1987	Assistant Professor - Rush, Presbyterian St. Luke's Medical Center, Rush University and Rush Medical School Department of Immunology/Microbiology, Chicago, IL 60612
July 1979-Dec 1987	Assistant Scientist Rush, Presbyterian St. Luke's Medical Center Department of Medicine, Chicago, IL 60612
Jul 1977-Jun 1979	Instructor/Postdoctoral Fellow Rush, Presbyterian St. Luke's Medical Center and Rush University Department of Immunology (H. Gewurz, MD) Chicago, IL 60612

July 1973-Dec 1977 Graduate Research Assistant
Northwestern University Feinberg School of Medicine
Department of Biochemistry, Chicago, IL 60611

Aug 1975-June 1977 Instructor
Illinois College of Podiatric Medicine
Now Merged with Roslyn Franklin University of Medicine and Science
Department of Biochemistry
Chicago, IL 60611

Sept 1970-May 1973 Research Associate/ Laboratory Manager
Bradley University
Department of Biology (A.G. Galsky, PhD)
Peoria, IL 61606

June 1972-Aug 1972 National Science Foundation Research Fellow
Northwestern University
Department of Biology (J.A. Lippincott, PhD)
Evanston, IL 60201

TEACHING and ADVISING EXPERIENCE

College/School of Pharmacy - Roosevelt University

Years taught	Courses	Course Responsibility and Title
2011 2012 2013 2014 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023	PHAR510	Course Director and Primary/Sole Instructor Biochemistry 1
2011 2012 2013 2014 2015, 2016 2017, 2018, 2019, 2020, 2021, 2022, 2023	PHAR511	Course Director and Primary/Sole Instructor Biochemistry 2
2024, 2025	PHAR 503	Foundational Sciences 1 Course Director and Primary/Sole Instructor Biochemistry (Consolidated course)
2011 2012 2013 2014/2015 2015/2016 2016/2017	PHAR512	Course Director 2011-2018 Primary Instructor Clinical Microbiology and Immunology

2017/2018 2018/2019 2019/2020 2021-2022 2022-2023 2023-2024		Co-Instructor 2019-present Taught all Immunology topics
2025	PHAR 603	Foundational Sciences IV – Microbiology/Immunology Taught all Immunology topics
2012 2013 2018, 2020	PHAR560	Course Director and Instructor Independent Research in Biochemistry and Immunology – Drug Discovery
2012	PHAR573	Course Director and Instructor Independent Research in Biochemistry and Immunology -2 – Drug Discovery
2012 2013 2014, 2018, 2020	PHAR 557	Course Director and Instructor The Drug Discovery Process
2011 2012	PHAR 540	Invited Lecture - Nutrition Biochemical Processes and Control of Metabolism
2011 2012 2013 2014	PHAR 633	Invited Lecture - Integrated Sequence VII – Musculoskeletal and Immune System Diseases Review of the Immune System – Structures, Cells and Mechanisms of Action
2012, 2013 2014, 2015 2016-2017 2018-2019	PHAR 654	Course Director and Instructor Biotherapeutic Drugs – Biochemical and Immunological Mechanisms of Action
2025	Industry Pharma Association	Faculty mentor of Roosevelt University's Industrial Pharmacy Organization (IPhO)

Rush University and Medical School

Years	Course and Academic responsibility
1985-1987	Graduate Program Director Graduate Division of Immunology
1984-1987	Graduate Advisory Committee Graduate Division of Immunology
1984-1987	Graduate College Task Force on Recruiting

1978-1987	Assistant Course Director Rush Medical School Basic and Clinical Immunology
1978-1987	Selected Lectures Rush Medical School Medical Immunology
1978-1987	Selected Lectures Rush Medical School Medical Microbiology
1978-1987	Course Director Rush University Graduate School Structure and Immunobiology of Membranes
1978-1987	Selected Lectures Rush University Graduate School Biology of Membranes
1978-1987	Course Director Rush University Graduate School Molecular Immunology
1978-1987	Selected Lectures Rush University Graduate School The Complement System of Host Defense
1978-1987	Course Director Rush University Graduate School Selected lectures: Biology of Membranes
1975-1977	Illinois College of Podiatric Medicine (now merged with Roslyn Franklyn University of Medicine and Science) Course Director (as a Visiting Professor) Medical Biochemistry (for Doctor of Podiatry Students)

Graduate and Undergraduate Students, Fellows and Visiting Professors under my tutelage

Scientific Trainee	Academic Position and Role	Years
Roosevelt University Pharmacy School/College PharmD Candidates		
Shams Azzawi (Pharm D Candidate)	Roosevelt University College of Pharmacy	2020
Mihee Lucia Choe (Pharm D Candidate)	Roosevelt University College of Pharmacy	2018
Jenna Kalsow (Pharm D Candidate)	Roosevelt University College of Pharmacy	2018
Joshua Grant (Pharm D Candidate)	Roosevelt University College of Pharmacy	2018
Stephen Copeland (Pharm D Candidate)	Roosevelt University College of Pharmacy	2012

Selma Kulasic (Pharm D Candidate)	Roosevelt University College of Pharmacy	2012
Iuliana Dumitrescu (Pharm D Candidate)	Roosevelt University College of Pharmacy	2012
Abdul (Vajiid) Rehmani (Pharm D Candidate)	Roosevelt University College of Pharmacy	2013
Biljana Stojavljevic (Pharm D Candidate)	Roosevelt University College of Pharmacy	2013
Yasser Rasheed (Pharm D Candidate)	Roosevelt University College of Pharmacy	2013
Meredith Imler (Pharm D Candidate)	Roosevelt University College of Pharmacy	2013
Marjan Motie, PhD	Postdoctoral Fellow Advisor Northwestern University Immtech International	1989-1992
Rush Medical Center –PhD candidates		
Elton B. Chu, PhD	Dissertation Advisor Rush University Graduate School	1989- 1991
Ruthann Rees, PhD	Dissertation Advisor Rush University Graduate School	1988-1990
Nancy L. Samberg, PhD	Dissertation Advisor Rush University Graduate School	1985-1987
Tod R. Fairbanks, PhD	Dissertation Advisor Rush University Graduate School	1981-1984
Rush Medical Center – Clinical Allergy/Immunology Fellows working in my laboratory		
Anne G Szpindor, MD	Rush Medical Center Allergy/Clinical Immunology Medical Fellow – Research Rotation	1985
Rita P Tarzynski-Potempa, MD	Rush Medical Center Allergy/Clinical Immunology Medical Fellow – Research Rotation	1986
Rush Medical Center – Professors on Sabatical working in my laboratory		
Phillipe Laurent, MD	From the Pasteur Institute, Lyon, France	1983
Manual Hernandez, MD	From the University of Caracas, Venezuela	1982

Undergraduate Students under my tutelage/mentoring

Year	Student Intern	Year	Student Intern
1980	T Costantino	1991	S Evascu
1981-1983	A Baron	1993	J Andrae
1984-1985	D Sutkowski	1994	B Press
1983-1985	A Orban	1995	S Brockmeier
1986	T Coogan	1999	N Furman
1987	S Coogan	2000, 2003	B Allen

1988	A Lichtenstein	2000-2003	RB Thompson
1988	B Gewurz	2004	V Ward
1989	R Huckman	2005	M Potempa
1990	A Radvany		

POST GRADUATE CONTINUING EDUCATION and SYMPOSIA

March 2015 Recertification Apr 2018	Certification in the Collaborative Institutional Training Initiative Program (CITI) for research involving human subjects (www.citiprogram.org) Completion Report # 15503596; Recertification Report #25493163
March 2015	The R'BIRTH Project Symposium on Psychoneuroimmunology Funded by the European Union Hasslet, Belgium
December 2011	Catalyzing Collaboration between Industry & Academia in the Life Sciences Advances in Tumor Immunology: Emerging Discovery, Translational & Diagnostic Approaches Abbott Laboratories Abbott Park, IL
April 2006	Boot Camp for Chief Scientific Officers iBIO Conference Chicago, IL
October 1984	Peptide and Protein Drug Delivery The Institute for Applied Pharmaceutical Sciences Center for Professional Advancement East Brunswick, NJ

HONORS, SCHOLARSHIPS and RESEARCH GRANT SUPPORT

April 2024 Dec 2025	Named as a Highly Ranked Scholar by Scholar GPS™ (Powering Scholarly Analytics). Recognizes exceptional performance in various fields, disciplines and specialties. Ranks publication record, high impact of work and outstanding quality of scholarly contributions. Ranked in the top 0.05% of all scholars worldwide In the field of C-reactive protein, I am recognized as Highly Ranked Scholar #18 (Lifetime) and #1 (in the prior 5 years)
November 2022 – October 2027	Co-PI for NIH RO1 grant with Boston University Medical School PI – Wendy Qiu, MD, PhD

Federal Award Project Title:

Identification and characterization of the CD31-ApoE-mCRP pathway for Alzheimer's disease in humans.

Award Number

1RF1AG075832-01A1

Unique Federal Award Identification Number (FAIN)

RF1AG075832

Statutory Authority

42 USC 241 42 CFR 52

Subcontract Awarded: \$25,000/year for 3 yrs (plus 57% overhead)

August 2019

Roosevelt University College of Pharmacy Distinguished Faculty Address to the class of 2022 - White Coat Ceremony

Roosevelt University - College of Pharmacy
Distinguished Faculty of the Year Award
Presented by the Graduating Class of 2019
Roosevelt University College of Pharmacy

April 2019

Collaborating investigator for The Ohio State University
P41 grant (Biotechnology Resource Grants) involving the analysis of CRP structural isoforms as part of DBP (Driving Biomedical Project) and C&S (Collaboration and Service) Projects entitled **"Resource for Native Mass Spectrometry Guided Structural Biology"** <https://nativems.osu.edu/team.php>

May 2018

"Most Difficult Exam Writer" Faculty Award from the Roosevelt University College of Pharmacy Student Class of 2020

June 2017 – 2018

Co-investigator **"mCRP in vascular dementia"**
Dementia Consortium
PI: Mark Slevin, PhD,
Manchester Metropolitan University, United Kingdom
Co-PI: Joannes Boltze, MD PhD
Fraunhofer Research Institution for Marine, Germany

June 2017 -2020

Member - **Task Force on Mental illness and inflammation**
World Federation of Societies of Biological Psychiatry
PI - Angelo Halaris, MD
Loyola University Stritch School of Medicine

July 2016 – 2018

Co-investigator
University of Medicine and Pharmacy
Tg Mures, Romania
Department of European Research Projects
Entitled: **"C-reactive protein therapy for stroke-associated dementia"**
(Principal investigator : Mark Slevin, PhD)

May 2015-2016	Co-investigator Roosevelt University College of Pharmacy Intramural Grant entitled: "Identification of isatin-based compounds as inhibitors of HIV integrase" (Principal Investigator : Sonali Kurup, PhD)
Apr 2014- present	Co-Investigator (in the United Kingdom) with Slevin M, Krupinski J, Potempa LA, Love S. Submitted grant to the Dementia Consortium (A joint initiative from Alzheimer's Research UK, MRC Technology, and industry partners to help progress new therapies for neurodegenerative disease to the clinic by funding collaborative drug discovery) entitled: "Monomeric-C-reactive protein clearance to reduce AD development after stroke"
May 2014	"Most Enthusiastic Faculty Award" from the Roosevelt University College of Pharmacy Student Advisory Class of 2016
May 2013	"Biggest Heart Award" – from the Roosevelt University College of Pharmacy Student Advisory Class of 2015. Recognizes "Outstanding dedication, relentless effort and exceptional encouragement"
Sept 2012	Advanced Practical Diagnostics (apDia), Belgium Gifted to LAPotempa and his Roosevelt University laboratory: ➤ apDia Plate Reader device base valued at 2137 € (\$2750) ➤ apDia Plate Washing device base valued at 1687 € (\$2,171) ➤ apDia Plate Shaker device base valued at 713 € (\$918 US)
Jan 2012-2014	European "EMTICS" project: "The interplay and occurrence of tics in relation to group A beta-haemolytic Streptococcus infection, genetic predisposition and stress" (http://ec.europa.eu/research/health/medical-research/brain-research/projects/emtics_en.html) (No direct expenses)
May 2012	"Biggest Heart Award" – from the Roosevelt University College of Pharmacy Student Advisory Council Inaugural Class of 2014. Recognizes "Outstanding dedication, relentless effort and exceptional encouragement"
Sept 2011	Faculty Representative Address to Pharm D students at the inaugural White Coat Ceremony Roosevelt University - College of Pharmacy
Apr 2010	Judge – Preliminary round competition for Northwestern University InNUvation entrepreneurial challenge Evanston, IL
Sep 2007-Feb 2008	Consultant/writer for a National Institutes of Health FDA Orphan Drug Products Development Grant "A Phase 3 Trial of Pafuramidine Maleate for the Treatment of Pneumocystis Pneumonia (PCP)" (\$1,050,000 over 3 yr) – <i>Declined when drug was dropped from clinical development after funding notice</i>
Aug 2004-Dec 2005	Principal Investigator of a National Institutes of Health Phase I SBIR Grant "Aromatic Dication Prodrugs for CNS Trypanosomiasis" (\$107,000)

Jan 2003-Dec 2005	Co-investigator for the Medicines for Malaria Ventures supported program to develop aromatic dications for malaria (total award in excess of \$2 million)
Jan 2002-Dec 2005	Co-investigator for the Bill and Melinda Gates Foundation supported program to develop Aromatic Dications drugs for African Sleeping Sickness and Leishmaniasis (total award in excess of \$15 million)
Sep 2000-Aug 2002	Co-investigator of a National Institutes of Health Phase II SBIR Grant “Novel Prodrugs for Treatment of Opportunistic Infections” (\$790,000)
June 2000-May 2001	Awarded a National Institutes of Health Phase I SBIR Grant – “Innate Immunity, C-reactive protein and Wound Healing” (\$107,000)
Apr 1999	Chief Scientist for Immtech International, Inc’s. Initial Public Offering (Raised \$11.5 million)
Apr 1999-Mar 2001	Awarded a National Institutes of Health Phase II SBIR Grant – “New Broad-Spectrum Drugs for Opportunistic Infections” (\$796,638)
Oct 1998-Jul 2002	Board Member – NextEra Therapeutics, Inc
Oct 1998-July 2002	Key Scientist, Vice President, Chief Scientific Officer and Founder NextEra Therapeutics, Inc. Responsible for the product and program of the company’s primary business and for raising \$1,350,000
5/98 – 4/99	Awarded a National Institutes of Health Phase I STTR Grant with Dr. David Boykin (Georgia State U) and Dr. Dennis Kyle (Walter Reed Medical Institute) - Dicationic prodrugs to treat tropical diseases. (\$100,000)
Feb 1998-Apr 1999	Co-Investigator of a National Institutes of Health Phase I STTR Grant with Dr. Howard Reisner (U North Carolina at Chapel Hill) “Immunoassays for pentamidine-like (dicationic) drugs. (\$100,000)
Jan 1990- Jun 2000	Vice President - Research and Chief Scientific Officer Immtech International Inc.
Jan 1990-Oct 1998	Directed and managed aspects of Immtech Int’l Inc.’s strategic therapeutic drug development programs as a key employee. Also helped raise operating capital in excess of \$7.5-million from private investors, venture capital, and corporate partners
June 1989	State of Wisconsin, Department of Development Innovation and Research Award
July 1988-Dec 1989	National Institutes of Health Phase 1 SBIR Grant. “Immune Complex binding by a modified form of C-reactive protein” (\$100,000)

Apr 1986	Who's Who Bradley University Academic Exploration Program
July 1985-Jun 1986	Rush Medical Center - Developmental Grant # 030058406
Jun 1985	Selected Graduate School "Hooder" at Rush University Commencement
Dec 1983-May 1986	Rush University Research Support Grants #97923, #97838, #47806, #97961
Sept 1978-June 1980	National Institutes of Health Postdoctoral Research Fellowship Rush Medical Center and University Department of Immunology/Microbiology
Jul 1973-Dec 1977	Northwestern University Graduate Research Fellowship Feinberg School of Medicine Department of Biochemistry, Chicago, IL
Sept 1969-May 1973	Bradley University Bachelor of Science Cum Laude <i>Honors Thesis entitled: "Studies on the Induction of Isocitrate Lyase in Hazel Seeds by GA₃ and Cyclic AMP"</i> May 1973
Sept 1969-May 1973	Illinois State Scholarship
Jun 1972-Aug 1972	National Science Foundation Undergraduate Research Program Fellowship Northwestern University, Evanston, IL (Dr. J.A. Lippincott) Project: "Role of Octopine Dehydrogenase in the Induction of Crown Gall Tumors in Pinto Beans"

PUBLICATIONS, BOOKS, and POSTERS

A. Research Articles:

- 1 **Potempa LA**, Galsky AG. 1973. The action of cyclic-AMP on GA₃ controlled responses V. Similarities in the induction of isocitrate lyase in hazel seeds by gibberellic acid and cyclic-3',5'-adenosine monophosphate. *Plant and Cell Physiology* 14: 989-995
- 2 **Potempa LA**, Garvin JE. 1976. A third form of the major glycoprotein of the human erythrocyte membrane in sodium dodecyl sulfate. *Biochem. Biophys. Res. Comm.* 72:1049-1055. [https://doi.org/10.1016/S0006-291X\(76\)80238-0](https://doi.org/10.1016/S0006-291X(76)80238-0)
- 3 **Potempa LA**. 1978. Characterization of a third form of the major erythrocyte membrane glycoprotein in sodium dodecyl sulfate. Ph.D. Dissertation. Northwestern University, Evanston, IL 60201
- 4 Dohnal JC, **Potempa LA**, Garvin JE. 1980. The molecular weights of the three forms of glycophorin A in sodium dodecyl sulfate solution. *Biochim. Biophys. Acta* 621:255-264. [http://doi:10.1016/0005-2795\(80\)90177-4](http://doi:10.1016/0005-2795(80)90177-4)
- 5 DiCamelli R, **Potempa LA**, Siegel J, Suyehira L, Petras K, Gewurz H. 1980. Binding reactivity of C-reactive protein for polycations. *J. Immunology* 125: 1933-1938

- 6 **Potempa LA**, Siegel J, Gewurz H. 1981. Binding reactivity of C-reactive protein for polycations. II Modulatory effects of calcium and phosphocholine. J. Immunology 127:1509-1514
- 7 Fiedel BA, **Potempa LA**, Frenzke ME, Simpson RM, Gewurz H. 1982. Platelet inhibitory effects of CRP preparations are due to a co-isolating low molecular weight factor. Immunology 45:15-22
- 8 **Potempa LA**, Siegel JN, Gewurz H. 1982. C-reactive protein (CRP) reactivity with polycations; modulatory role for calcium, phosphocholine (PC) and heparin. Annals of the New York Acad. Sci. 389:461-462
- 9 Dougherty T, **Potempa LA**, Gewurz H, Siegel J. 1982. Binding reactivity of rabbit CxRP for polycations. Annals of the New York Acad. Sci. 389: 444-445
- 10 **Potempa LA**, Gewurz H. 1983. Influence of heparin on interactions between C-reactive protein and polycations. Mol. Immunol. 20:501-509 [http://DOI:10.1016/0161-5890\(83\)90088-3](http://DOI:10.1016/0161-5890(83)90088-3)
- 11 Laurent P, **Potempa LA**, Gewurz H, Fiedel B A, Allen R. 1983. The titration curve of native C-reactive protein. Electrophoresis 4:316-317
- 12 **Potempa LA**, Maldonado BA, Laurent P, Zemel E, Gewurz H. 1983. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol. Immunol. 20: 1165-1175. [http://doi:10.1016/0161-5890\(83\)90140-](http://doi:10.1016/0161-5890(83)90140-)
- 13 Marder RJ, **Potempa LA**, Jones JV, Toriumi D, Schmid FR, Gewurz, H. 1984. Assay, purification and further characterization of 7S C1q-precipitins (C1q-p) in hypocomplementemic vasculitis urticarial syndrome and systemic lupus erythematosus. Acta Path. Microbiol. Immunol. Scand., Sect. C. Suppl. 284, 92: 25-34
- 14 **Potempa LA**, Kubak BM, Gewurz H. 1985. Effect of divalent metal ions and pH upon the binding reactivity of human serum amyloid P-component, a C-reactive protein homologue, for zymosan. Preferential reactivity in the presence of copper and acidic pH. J. Biol. Chem. 260:12142-12147
- 15 **Potempa LA**, Gewurz H, Harris JE, Braun DP. 1986. Stimulatory effects of the C-reactive protein subunit on monocyte function, including release of IL-I. Protides of the Biological Fluids. 34:287-290
- 16 Kubak BM, **Potempa LA**, Gewurz A, Slodki ME, Venegas M, Anderson B, Gewurz, H. 1986. Binding of Serum Amyloid P-component (SAP) to soluble Saccharomyces cerevisiae zymosan extract and yeast mannans and phosphomannans. Protides of the Biol. Fluids. 34:391-394
- 17 Dougherty TJ, Zeller JM, **Potempa LA**, Gewurz H, Siegel J. 1986. Effects of pentamer, peptide and aggregate forms of rabbit C-reactive protein on PMNL activation. Protides of the Biological Fluids.34:291-293

- 18 **Potempa LA**, Siegel JN, Fiedel BA, Potempa RT, Gewurz H. 1987. Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free C-reactive protein subunit. *Mol. Immunol.* 24:531-541. [http://doi:10.1016/0161-5890\(87\)90028-9](http://doi:10.1016/0161-5890(87)90028-9)
- 19 Bray RA, Samberg NL, Landay AL, Gewurz H, **Potempa LA**. 1987. Identification of a novel antigenic specificity present on the surface of human natural killer cells and B-lymphocytes. *Clin. Immunol. Newsletter* 8(9):137-140. [https://doi.org/10.1016/0197-1859\(87\)90060-4](https://doi.org/10.1016/0197-1859(87)90060-4)
- 20 **Potempa LA**, Zeller JM, Fiedel BA, Kinoshita CM, Gewurz H. 1988. Stimulation of human neutrophils, monocytes and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. *Inflammation* 12:391-405
- 21 Kubak BM, **Potempa LA**, Anderson B, Mahklouf S, Venegas M, Gewurz H, Gewurz AT. 1988. Evidence that serum amyloid P-component binds to mannose-terminated sequences of polysaccharides and glycoproteins. *Mol. Immunol.* 25:851-858. [http://doi:10.1016/0161-5890\(88\)90121-6](http://doi:10.1016/0161-5890(88)90121-6)
- 22 Rees RF, Gewurz H, Siegel JN, Coon J, **Potempa LA**. 1988. Expression of a C-reactive protein neo-antigen (Neo-CRP) in inflamed rabbit liver and muscle. *Clinical Immunology and Immunopathology* 48:95-107
- 23 Bray RA, Samberg NL, Gewurz H, **Potempa LA**, Landay AL. 1988. C-reactive protein antigenicity on the surface of human peripheral blood lymphocytes. Characterization of lymphocytes reactive with anti-neo-CRP. *J. Immunol.* 40:4271-4278
- 24 Kubak BM, Gewurz H, **Potempa LA**. 1988. Identification of multiple forms of the P-component of amyloid isolated from human serum. *International Archives of Allergy and Applied Immunology* 87:194-203 <http://doi:10.1159/000234672>
- 25 Samberg NL, Bray RA, Gewurz H, Landay AL, **Potempa LA**. 1988. Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes. *Cellular Immunol.* 116:86-98. [http://doi.org/10.1016/0008-8749\(88\)90212-2](http://doi.org/10.1016/0008-8749(88)90212-2)
- 26 Ying S-C, Gewurz H, Kinoshita CM, **Potempa LA**, Siegel JN. 1989. Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein using monoclonal antibodies. *J. Immunol.* 143:221-228.
- 27 Kinoshita CM, Ying S-C, Hugli TE, Siegel JN, **Potempa LA**, Jiang H, Houghton RA, Gewurz H. 1989. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. *Biochemistry* 28:9840-9848 <http://doi:10.1021/bi00451a044>
- 28 **Potempa LA**, Anderson BE. 1990. Selective adsorption of Immunoglobulin G on affinity matrices containing a modified form of human C-reactive protein. *Proceedings of the International Congress on Membranes and Membrane Processes Vol 1:* 169-171
- 29 Shields MJ, Siegel JN, Clark CR, Hines KK, **Potempa LA**, Gewurz H, Anderson B. 1991. An appraisal of polystyrene (ELISA) and nitrocellulose-based enzyme immunoassay systems using monoclonal antibodies reactive toward antigenically distinct forms of human C-reactive protein. *J. Immunol. Methods* 141:253-261

- 30 **Potempa LA**, Motie M, Anderson B, Klein E, Baurmeister U. 1991. Conjugation of a modified form of human C-reactive protein to affinity membranes for extracorporeal adsorption. *Clinical Materials* 11:105-117
- 31 **Potempa LA**, Motie M, Wright KE, Crump BL, Radosevich JA, Sakai N, Lai G, Tanaka K, Kojima E, Tsuboi A. 1996. Stimulation of megakaryocytopoiesis in mice by human modified-C-reactive protein (mCRP). *Experimental Hematology* 24:258-264
- 32 Motie M, Brockmeier S, **Potempa LA** 1996. Characteristics of the binding of model soluble immune complexes to modified-C-reactive protein. *J. Immunology* 156:4435-4441
- 33 Vaith P, Prasauskas V, **Potempa LA**, Hansch GM, Peter HH. 1996. Complement activation by C-reactive protein on the HEp-2 cell substrate. *Int. Archives of Allergy and Applied Immunology* 111:107-117. <https://doi.org/10.1159/000237354>
- 34 **Potempa LA**, Kresl JJ, Anderson BE. 1997. Methods for imaging cancer cells using modified C-reactive protein. *Biotechnology Advances* 15:1 [http://doi:10.1016/S0734-9750\(97\)88451-0](http://doi:10.1016/S0734-9750(97)88451-0)
- 35 **Potempa LA**. 1997. Methods of stimulating thrombopoiesis using modified C-reactive protein. *Biotechnology Advances* 15:2 [http://doi:10.1016/S0734-9750\(97\)82281-1](http://doi:10.1016/S0734-9750(97)82281-1)
- 36 Kresl JJ, **Potempa LA**, Anderson BE. 1998. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. *Int'l J Biochemistry and Cell Biology* 30:1415-1426
- 37 Motie M, Schaul KW, **Potempa LA**. 1998. A study of the plasma clearance and biodistribution characteristics of human ¹²⁵I-mCRP in the mouse. *Drug Metabolism and Disposition* 26:977-981
- 38 Suankratay C, Mold, C, Zhang Y, **Potempa LA**, Lint TF, Gewurz, H. 1998. Complement regulation in the acute phase response: inhibition of mannose-binding lectin-initiated complement cytolysis by C-reactive protein. *Clin Exp'l Immunol* 113:353-359
- 39 Diehl EE, Radosevich JA, Haines III GK, Yokoo H, **Potempa LA**. 1998. Cellular effects of the modified form of C-reactive protein (mCRP) on tumor cells. 17th International Cancer Congress 24-28 Aug -Rio DeJaniero, Brazil, 167-170
- 40 Kresl JJ, **Potempa LA**, Anderson B, Radosevich JR. 1999. Inhibition of Mouse Adenocarcinoma (EMT6) Growth and Metastases in Mice by a Modified Form of C-Reactive Protein. *Tumor Biology* 20:72-87 <http://doi:10.1159/000030050>
- 41 Diehl EE, Haines GK, Radosevich JA, **Potempa LA**. 2000. Immunohistological localization of modified C-reactive protein antigen in normal human vascular tissue. *Amer J Med Sci*. 319:79-83 <http://DOI:10.1097/00000441-200002000-00002>
- 42 Vaith P, **Potempa LA**. 2000. Deposition of modified or native C-reactive protein in atherosclerotic arteries? (Letter to the editor) *Arteriosclerosis, Thrombosis, Vascular Biology* April 20:1173-1174 <https://doi.org/10.1161/01.ATV.20.4.117>

- 43 Zouki C, Haas B, Chan JCD, **Potempa LA**, Filep JG. 2001. Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. *J Immunol* 167:5355-5361. <https://doi.org/10.4049/jimmunol.167.9.5355>
- 44 Khreiss T, József L, Hossain S, Chan JSD, **Potempa LA**, Filep JG. 2002. Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. *J Biol Chem* 277:40775-40781. <http://doi:10.1074/jbc.M205378200>
- 45 Schwedler SB, Guderian F, Dämmrich J, **Potempa LA**, Wanner C. 2003. Tubular Staining of Modified C-Reactive Protein Increases with Severity of Diabetic Nephropathy. *Nephrology Dialysis Transplantation* 18:2300-2307 <http://doi:10.1093/ndt/gfg407>
- 46 Khreiss T, József L, **Potempa LA**, Filep JG. 2004. Conformational Rearrangement in C-Reactive Protein is Required for Proinflammatory Actions on Human Endothelial Cells. *Circulation* 109:2016-2022. <http://doi:10.1161/01.CIR.0000125527.41598.68>
This article was the topic of a Focused Perspective by the Editors of Circulation. The article was entitled "C-reactive protein – Structure Affects Function by Verma S, Szmitko PE, Yeh ETH (2004) 109:1914-1917
- 47 Khreiss T, József L, **Potempa LA**, Filep JG. 2004. Opposing Effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. *Circulation* 110:2713-2720 <https://doi.org/10.1161/01.CIR.0000146846.00816.DD>
- 48 Heuertz RM, Schneider GP, **Potempa LA**, Webster RO. 2005. Native and modified C-reactive protein bind different receptors on human neutrophils. *Int'l J Biochemistry and Cell Biology* 37:320-335 <https://doi.org/10.1016/j.biocel.2004.07.002>
- 49 Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, **Potempa LA**, Galle J 2005. Native C-reactive protein (CRP) increases, whereas modified CRP reduces atherosclerosis in ApoE-knockout-mice. *Circulation* 112(7):1016-23. <http://doi:10.1161/CIRCULATIONAHA.105.556530>
- 50 Ciubotaru I, Lee YS, **Potempa LA**, Wander RC. 2005 The production of modified C-reactive protein in U937-derived macrophages. *Exp Biol Med* 230 (10):762-770
- 51 Khreiss T, József L, **Potempa LA**, Filep JG. 2005. Loss of pentameric symmetry in C-reactive protein induces Interleukin-8 secretion through peroxynitrite signaling in human neutrophils. *Circulation Research* 97:690-697 <http://doi:10.1161/01.RES.0000183881.11739.CB>
This article was the topic of an Editorial by Edward TH Yeh in Circulation Research. The article was entitled "A New Perspective on the Biology of C-reactive protein" Cir Res 2005; 97:609-611
- 52 Schwedler SB, Filep JG, Galle J, Wanner C, **Potempa LA**. 2006 C-reactive protein: a family of proteins to regulate cardiovascular function. *American J Kidney Disease* 47:212-222. Review. <http://doi:10.1053/j.ajkd.2005.10.028>

-
- 53 Ji SR, Wu Y, **Potempa LA**, Qiu Q, Zhao J. 2006. The interactions of low-density lipoprotein with different forms of C-reactive protein: implication of an active role of modified C-reactive protein in the pathogenesis of atherosclerosis. *International Journal of Biochemistry and Cell Biology* 38:648-661 <https://doi.org/10.1016/j.biocel.2005.11.004>
- 54 Ji SR Wu Y, **Potempa LA**, Liang Y-H, Zhao J. 2006. Effect of modified C-reactive protein on complement activation: A possible complement regulatory role of mCRP in atherosclerotic lesions. *Atherosclerosis Thrombosis and Vascular Biology* 26:935-941 <https://doi.org/10.1161/01.ATV.0000206211.21895.73>
- 55 Ji SR, Wu Y, Zhu L, **Potempa LA**, Sheng FL, Wei L, Zhao J. 2007. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP_m. *FASEB J* 21:284-294. <http://doi:10.1096/fj.06-6722com>
- 56 Boguslawski G, McGlynn PW, **Potempa LA**, Filep JG, Labarrere CA. 2007 Conduct Unbecoming: C-reactive protein interactions with a broad range of protein molecules. *J Heart Lung Transplant* 26:705-713 <http://doi:10.1016/j.healun.2007.04.006>
- 57 Schwedler SB, Kuhlencordt PJ, Ponnuswamy PP, Hatiboglu G, Quaschnig T, Widder J, Wanner C, **Potempa LA**, Galle J. 2007. Native C-reactive protein induces endothelial cell dysfunction in ApoE^{-/-} mice: Implications for iNOS and reactive oxygen species. *Atherosclerosis* 195(2):e76-84. <http://doi:10.1016/j.atherosclerosis.2007.06.013>
- 58 Wu Y, Ji SR, **Potempa LA**, Filep JG. 2007. Structural transition from pentamer to monomer: A mechanism for regulation of C-reactive protein bioactivities. *Atherosclerosis Commentaries*. www.athero.org/commentaries/comm537.asp.
- 59 Filep, JG, Khreiss T, József L, **Potempa LA**, El Kebir D. 2008. Does C-reactive protein orchestrate inflammation in acute coronary artery disease? *Proceedings of the 2007 Int'l Symposium on Atherosclerosis, Thrombosis and Vascular Biology*
- 60 Ji S-R, Bai L, Shi J-M, Li H-Y, **Potempa LA**, Filep JG, Zhao J, Wu Y. 2009. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft membrane microdomains. *FASEB J* 23(6):1806-1816 <http://doi:10.1096/fj.08-116962>
- 61 Schwedler SB, Hansen-Hagge T, Reichert M, Schmiedeke D, Schneider R, Galle J, **Potempa LA**, Wanner C, Filep JG. 2009. Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. *Clinical Chem* 55:1728-1731 <http://doi:10.1373/clinchem.2009.125732>
- 62 Singh SK, Suresh MV, Rusiñol AE, **Potempa LA**, Agrawal A. 2009. Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. *Clin Chim Acta* 406:151-155 <http://doi:10.1016/j.cca.2009.06.018>
- 63 Slevin M, Rovina N, Turu M, Luque L, Badimon L, Gaffney J, **Potempa L**, Krupinski J. 2009. Modified C-reactive protein is expressed in adventitia and intimal neovessels from complicated regions of unstable carotid plaques. *The Open Circulation and Vascular Journal*. 2: 23-29. <http://doi:10.2174/1877382600902010023>
-

-
- 64 Hammond DJ, Singh SK, Pangburn MK, **Potempa LA**, Agrawal A. 2010. Requirement of acidic pH for the binding of C-reactive protein to factor H. *Mol Immunol* 47(13):2249-2250 <http://doi:10.1016/j.molimm.2010>
- 65 Slevin M, Matou-Nasri S, Turu MM, Luque A, Rovira N, Badimon L, Boluda S, **Potempa LA**, Sanfeliu C, de Vera N, Krupinski J. 2010. Modified C-reactive protein is expressed by stroke neo-vessels and is a potent activator of angiogenesis *in vitro*. *Brain Pathol* 20:151-165 <http://doi:10.1111/j.1750-3639.2008.00256.x>
- 66 Hammond Jr DJ, Singh SK, Thompson JA, Beeler BW, Rusiñol AE, Pangburn MK, **Potempa LA**, Agrawal A. 2010. Identification of acidic pH dependent ligands of pentameric C-reactive protein *J Biol Chem* 285:36235-36244 <http://doi:10.1074/jbc.M110.142026>
- 67 Boncler M, Rywaniak J, Szymanski J, **Potempa LA**, Rychlik B, Watala C. 2011. Modified C-reactive protein interacts with platelet glycoprotein Ib α . *Pharmacological Reports* 63:464-475
- 68 Wang M-Y, Ji S-R, Bai C-J, El Kebir D, Li H-Y, Shi J-M, Zhu W, Costantino S, Zhou H-H, **Potempa LA**, Zhao J, Filep JG, Wu Y. 2011. A redox switch in C-reactive protein modulates activation of endothelial cells. *FASEB J.* 25:3186-3196 <http://doi:10.1096/fj.11-182741>
- 69 El Kebir D, Zhang Y, Wang L, **Potempa LA**, Wu Y, Fournier A, Filep JG. 2011. C-reactive protein-derived peptide 201-206 inhibits neutrophil adhesion to endothelial cells and platelets through CD32. *Journal of Leukocyte Biology* 90(6):1167-1175 <http://doi:10.1074/jlb.0111032>
- 70 Paradise WA, Vesper BJ, Babich M, **Potempa LA**, Colvard MD, Radosevich JA. 2011. Methods, Processes and Comparative Yield Economics for the production of antibodies and other recombinant proteins (Review). *Immunology Endocrine & Metabolic Agents - Medicinal Chemistry* 11 (3) 199-219. <http://doi:10.2174/18715221179664278>
- 71 Boras E, Slevin M, Alexander MY, Gilmore W, Ashworth J, Krupinski J, **Potempa LA**, Abuulkareem IA, Matou-Nasri S. 2014. Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signaling pathway. *Cytokine*. Oct;69(2):165-179 <http://doi:10.1016/j.cyto.2014.05.027>
- 72 Li H-Y, Wang J, Wu Y-X, Zhang L, Liu Z-P, Filep JG, **Potempa LA**, Wu Y, Ji S-R. 2014. Topological Localization of Monomeric C-reactive Protein Determines Pro-inflammatory Endothelial Cell Responses. *J Biol Chem.* May 16;289(20):14283-14290 <http://doi:10.1074/jbc.M114.555318>
- 73 Zhang L, Liu S-H, Wright TT, Shen Z-Y, Li H-Y, Zhu W, **Potempa LA**, Ji S-R, Szalai AJ, Wu Y. 2015. C-reactive Protein directly suppresses T helper 1 cell differentiation and alleviates experimental autoimmune encephalomyelitis. *J Immunology* 194(11):5243-5252. <http://doi:10.4049/jimmunol.1402909>
- 74 **Potempa LA**, Yao Z-Y, Ji S-R, Filep JG, Wu Y. 2015. Solubilization and purification of recombinant modified C-reactive protein from inclusion bodies using reversible anhydride modification. *July 2015 - Biophysics Reports* 1 (1):18-33. <http://doi:10.1007/s41048-015-0003-2>
-

-
- 75 Wu Yi, **Potempa LA**, El Kebir D, Filep JG. 2015. C-reactive protein and inflammation: conformational changes affect function. *Biol Chem* 396(11):1181-1197. <http://doi:10.1515/hsz-2015-0149>
- 76 Slevin M, Matou S, Zeinolabediny Y, Corpas R, Weston R, Di Napoli M, Petcu E, Sarroca S, Popa-Wagner A, Love S, Font MA, **Potempa LA**, Al-Baradie R, Sanfeliu C, Revilla S, Badimon L, Krupinski J. 2015. Monomeric C-reactive protein-a key molecule driving development of Alzheimer's disease associated with brain ischaemia? *Scientific Reports* 5:13281-13302 <http://doi:10.1038/srep13281>
- 77 Li H-Y, Jing Wang J, Meng F, Zhe-Kun Jia Z-K, Su Y, Bai Q-F, Lv L-L, Ma F-R, **Potempa LA**, Yan Y-B, Ji S-R, Wu Y. 2016. An intrinsically disordered motif mediates diverse actions of monomeric C-reactive protein. *J Biol Chem* 291(16):8795-8804 <http://doi:10.1074/jbc.M115.695023>
- 78 Chirco KR, Whitmore SS, Wang K, **Potempa LA**, Halder JA, Stone EM, Tucker BA, Mullins RF. 2016. Monomeric C-reactive protein (mCRP) and inflammation in Age-related Macular degeneration. The role of monomeric C-reactive protein in AMD. *J Pathology* 240(2):173-183 <http://doi:10.1002/path.4766>
- 79 Trial J, **Potempa LA**, Entman ML 2016. The Role of C-reactive Protein in Innate and Acquired Inflammation: New Perspectives. *Inflammation and Cell Signaling* 3:e1409 <http://doi:10.14800/ics.1409>
- 80 Braig D, Nero TL, Koch H-G, Kaiser B, Wang X, Thiele JR, Zeller J, Kiefer J, Morton C, **Potempa LA**, Mellett NA, Miles LA, Du X-J, Meikle PJ, Huber-Lang M, Stark GB, Parker MW, Peter K, Eisenhardt SU. 2017. Characterization of transitional changes in the CRP structure leading to the exposure of pro-inflammatory binding sites. *Nature Communications* 23(8):14188 <http://doi:10.1038/ncomms14188>
- 81 Boras E, Slevin M, Gilmore W, **Potempa LA**, Matou-Nasri S. 2017. Common angiogenic signaling pathways induced by monomeric-CRP and FGF-2 through MAP and PI3K. *European J Exp Biol* 7:18-29
- 82 Lv J-M, Lü S-Q, Zhang J, Liu Z-P, Gao B-X, Yao Z-Y, Wu Y-X, **Potempa LA**, Ji S-R, Long M, Wu Y. 2018. Conformational folding and disulfide bonding drive distinct stages of protein structure formation. *Scientific Reports* 24;8(1):1494-1504. (Jan) <http://doi:10.1038/s41598-018-20014-y>
- 83 Jia Z-K, Li H-Y, Liang Y-L, **Potempa LA**, Ji S-R, Wu Yi. 2018. Monomeric C-reactive protein binds and neutralizes receptor activator of NF- κ B Ligand-induced osteoclast differentiation. *Frontiers in Immunology* 9:234 February <http://doi.org/10.3389/fimmu.2018.00234>. Erratum Nov 2020: <http://doi:10.3389/fimmu.2020.619847>
- 84 Chirco, KR, **Potempa LA**. 2018. C-reactive Protein as a Mediator of Complement Activation and Inflammatory Signaling in Age-related Macular Degeneration. Mini-Review. *Frontiers in Immunology-Inflammation* 9:article 539. Mar 15, 2018. <http://doi:10.3389/fimmu.2018.00539>
-

-
- 85 Thiele JR, Zeller J, Kiefer J, Braig D, Kreuzaler S, Lenz Y, **Potempa LA**, Grahammer F, Huber TB, Huber-Lang M, Bannasch H, Stark BG, Peter K, Eisenhardt SU. 2018. A conformational change in C-reactive protein enhances leukocyte recruitment and reactive oxygen species generation in ischemia/reperfusion injury. *Front. Immunol.* 9:675-690. <http://doi:10.3389/fimmu.2018.00675>
- 86 McFadyen J, Kiefer J, Loseff-Silver J, Braig D, **Potempa LA**, Eisenhardt SU, Peter K. 2018. Dissociation of C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of CRP and its conformational changes. *Frontiers in Immunology Vol 9: Article 1351*. <http://doi.10.3389/fimmu.2018.01351.ecollection>
- 87 Chirco KR, Flamme-Wiese MJ, Wiley JS, **Potempa LA**, Stone EM, Tucker BA, Mullins RF. 2018. Evaluation of serum and ocular levels of membrane attack complex and C-reactive protein in CFH-genotyped human donors. *Eye* 32(11):1740-1742 <http://doi10.1038/s41433-018-0170-8>
- 88 Li H-Y, Liu X-L, Liu Y-T, Jia Z-K, Filep JG, **Potempa LA**, Ji S-R, Wu Y. 2018. Matrix sieving-enforced retrograde transcytosis regulates tissue accumulation of C-reactive protein. *Cardiovascular Res.* 9 July 2018. <http://doi10.1093/cvr/cvy181>
- 89 Yao Z, Zhang Y, **Potempa LA**, Rajab I, Ji L, Lv J, Zhang L, Wu H. 2019. A redox sensitivity-based method to quantify both pentameric and monomeric C-reactive protein in a single assay. *J Immuno Methods* 470:40-45. <http://doi:10.1016/j.jim.2019.04.009>
- 90 Rajab IM, Majerczyk D, Olson ME, Addams JMB, Choe ML, Nelson MS, **Potempa LA**. 2020. C-reactive protein in gallbladder diseases – diagnostic and therapeutic insights. *Biophysics Report* 6(2-3):49-67. <http://doi:10.1007/s41048-020-00108-9> On line access: <https://rdcu.be/b41Rz>
- 91 **Potempa LA**, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. 2020. Insights into the use of C-reactive protein (CRP) as a diagnostic index of disease severity in COVID-19 infections. *American Journal of Tropical Medicine and Hygiene* 103 (2):561-563. <http://doi10.4269/ajtmh.20-0473>
- 92 Rajab IM, Hart PC, **Potempa LA**. 2020. How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression. *Frontiers Immunology – Molecular Innate Immunity* 112:126-2138. <http://doi:10.3389/fimmu.2020.02126>
- 93 Hart PC, Rajab IM, Alebraheem M, **Potempa LA**. 2020. C-reactive protein and cancer – diagnostic and therapeutic insights. *Frontiers Immunology – Molecular Innate Immunity* 11:595835. <http://doi:10.3389/fimmu.2020.595835>
- 94 Ruiz-Fernández C, Francisco V, Gonzalez M, Rajab I, Gómez R, Conde J, Lago F, Pino J, Mobasheri A, **Potempa LA**, Gualillo O. 2021. Monomeric C Reactive Protein (mCRP) regulates inflammatory responses in human and mouse chondrocytes. *Laboratory Investigation*. <https://doi.org/10.1038/s41374-021-00584-8> Online access: <https://rdcu.be/chs91>
-

-
- 95 Zhang Z, Na H, Gan Q, Tao Q, Gower A, Hu J, Yan Z, Yang JB, Tian H, Zhu E, Li Q, Blusztajn JK, Wolozin B, Emili A, Zhang X, Stein T, Rajab IM, **Potempa LA**, Qiao Qiu W. 2021. The ApoE4-related pathway involving monomeric C-reactive protein and phosphorylation of CD31 induces cerebrovascular damage and extravasation of T lymphocytes, leading to Alzheimer's disease. <http://doi:10.1101/2021.05.30.446344>
- 96 Zhang Z, Na H, Gan Q, Tao Q, Alekseyev Y, Hu J, Yan Z, Yang JB, Tian H, Zhu S, Li Q, Rajab IM, Blusztajn JK, Wolozin B, Emili A, Zhang X, Stein T, **Potempa LA**, Qiu WQ. 2021. Monomeric C-reactive protein via endothelial CD31 for neurovascular inflammation in an ApoE genotype-dependent pattern: A risk factor for Alzheimer's disease? *Aging Cell*, 20:e13501. <https://doi.org/10.1111/acer.13501>
- 97 **Potempa LA**, Rajab IM, Olson ME, Hart PC. 2021. C-reactive protein and cancer. Interpreting the differential bioactivities of its pentameric (pCRP) and monomeric, modified (mCRP) isoforms. *Frontiers – Immunology* 12:744129-744140. <http://doi:10.3389/fimmu.2021.744129>
- 98 Cheng B, Lv JM, Liang YL, Zhu L, Huang XP, Li HY, **Potempa LA**, Ji SR, Wu Y. 2022. Secretory quality control constrains functional selection-associated protein structure innovation. *Commun Biol.* Mar 25;5(1):268. <http://doi:10.1038/s42003-022-03220-3>
- 99 Gan Q, Wong A, Zhang Z, Na H, Tian H, Tao Q, Rajab IM, **Potempa LA**, Qiu WQ. 2022. Monomeric C-reactive protein induces the cellular pathology of Alzheimer's disease. *Alzheimer's Dement* 8:e12319-12332. <http://DOI:10.1002/trc2.12319>
- 100 **Potempa LA**, Qiu WQ, Stefanski A, Rajab IM. 2022. Relevance of lipoproteins, membranes, and extracellular vesicles in understanding C-reactive protein (CRP) biochemical structure and biological activities. *Frontiers in Cardiovascular Medicine, Atherosclerosis and Vascular Medicine* 9:979461-979476. <http://doi:10.3389/fcvm.2022.979461>
- 101 Svanberg C, Helena Enocsson H, Govender M, Martinsson K, **Potempa LA**, Rajab IM, Fernandez-Botran R, Wetterö J, Larsson M, Sjöwall C. 2023. Conformational state of C-reactive protein is critical for reducing immune complex-triggered type I interferon response: Implications for pathogenic mechanisms in autoimmune diseases imprinted by type I interferon gene Dysregulation, *J Autoimmunity* 135:102998-103009. <http://doi.org/10.1016/j.jaut.2023.102998>
- 102 Karlsson J, Wetterö J, **Potempa LA**, O'Neill Y, Wirestam L, Mobarrez F, Sjöwall C. 2023. Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP. *J Autoimmunity* 139:103073. <http://doi:10.1016/j.jaut.2023.103073>
- 103 Køstner AH, Fuglestad AJ, Georgsen JB, Nielsen PS, Christensen KB, Zibrandtsen H, Parner ET, Rajab IM, **Potempa LA**, Steiniche T, Kersten C. 2023 Fueling the flames of colon cancer – does CRP play a direct pro-inflammatory role? *Front Immunol* 14:1170443-1170455. <http://doi:10.3389/fimmu.2023.1170443>
-

-
- 104 Na H, Yang JB, Zhang Z, Gan Q, Tian H, Rajab IM, **Potempa LA**, Tao Q, Qiu WQ. 2023. Peripheral apolipoprotein E proteins and their binding to LRP1 antagonize Alzheimer's disease pathogenesis in the brain during peripheral chronic inflammation. *Neurobiology of Aging* 127 (July):54-69. <https://doi.org/10.1016/j.neurobiolaging.2023.02.013>
- 105 Pastorello Y, Carare RO, Banescu C, **Potempa L**, Di Napoli M, Slevin M. 2023. Monomeric C-reactive protein: A novel biomarker predicting neurodegenerative disease and vascular dysfunction. *Brain Pathol.* May 9:e13164. <http://doi:10.1111/bpa.13164>
- 106 Boras E, Slevin M, Gilmore W, **Potempa LA**, Matou-Nasri S. 2023. Common Angiogenic Signaling Pathways Induced by Monomeric C-reactive protein and FGF-2 through MAPK and PI3K. *European J Exp Biol* In press
- 107 Olson ME, Hornick MG, Stefanski A, Albanna H, Gjoni A, Hall GD, Hart PC, Rajab IM, **Potempa LA**. 2023. A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: Differentiating pentameric and modified CRP isoform effects. *Frontiers Immunology* 14:1264383. <http://doi:10.3389/fimmu.2022.1002652>
- 108 Hornick MG, **Potempa LA**. 2024. Monomeric C-reactive protein as a biomarker for major depressive disorder. *Front Psychiatry* 14:1325220. <http://doi:10.3389/fpsy.2023.1325220>
- 109 Pastorello Y, Manu D, Sawkulycz X, Caprio V, Banescu C, Dobreanu M, **Potempa L**, Di Napoli M, Slevin M. 2024 mCRP-Induced Focal Adhesion Kinase-Dependent Monocyte Aggregation and M1 Polarization Which Was Partially Blocked by the C10M Inhibitor. *Int J Mol Sci* 25:3097. <https://doi.org/10.3390/ijms25063097>
- 110 Pastorello Y, Russo AP, Bănescu C, Caprio V, Gáll Z, **Potempa LA**, Cordoş B, Di Napoli M, Slevin M. 2024. Brain Vascular Expression of Monomeric C-Reactive Protein is Blocked by C10M following Intraperitoneal Injection, in an ApoE-/- Murine Model of Dyslipidaemia: An Immunohistochemical Analysis. *Cureus* 16(5): e60682. <http://doi:10.7759/cureus.60682>
- 111 Zhang Z, Lin W, Gan Q, Lei M, Gong B, Zhang C, Henrique JS, Han J, Tian H, Tao Q, **Potempa LA**, Stein TD, Emili A, Qiu WQ. The influences of ApoE isoforms on endothelial adherens junctions and actin cytoskeleton responding to mCRP. *Angiogenesis*. 2024 Sep 14. <http://doi:10.1007/s10456-024-09946-4>
- 112 Mulfaul K, Khan AH, Schwarte SG, Voigt AP, Moore RF, **Potempa LA**, Wang K, Scheetz TE, Stone EM, Tucker BA, Mullins RF. 2024. Elevation of Granulocyte Colony Stimulating Factor in Human AMD Donor RPE-Choroid. *Invest Ophthalmol Vis Sci* 65(14):15. <http://doi:10.1167/iovs.65.14.15>
- 113 Potempa M, Hart PC, Rajab IM, **Potempa LA**. 2025. Redefining CRP in Tissue Injury and Repair: More Than an Acute Pro-inflammatory Mediator. *Frontiers in Immunology - Molecular Innate Immunity* 16:1564607. Research Topic: Community Series in Biology of C-reactive Protein. <http://doi:10.3389/fimmu.2025.1564607>
-

- 114 Fuglestad AJ, Bousquet PA, Køstner AH, Meltzer S, Kleist B, Ree AH, Rajab IM, **Potempa LA**, Fernandez-Botran R, Kersten C. 2025. Circulating levels of the proinflammatory monomeric isoform of C-reactive protein (mCRP) correlate with intra-tumoral mCRP abundance in stage II-III colon cancer patients. *Inflammation Research* 18:7115-7125. <https://doi.org/10.2147/JIR.S485050>
- 115 Ahmed M, Yuan P, Lei JG, Tang ZM, Yang ZR, **Potempa LA**, Wang HY, Li HY. From Homeostasis To Inflammation To Autoimmunity: The Potential Impact of CRP. *Inflammation*. 2025 Jul 18. <http://doi:10.1007/s10753-025-02303-7>
- 116 Potempa M, Rajab IM, Margaret E Olson ME, Lv J, Yao Z, **Potempa LA**. 2025. Allosteric Regulation of C-reactive Protein. *Biophysics Report*. <http://DOI:10.52601/bpr.2025.250041>
- 117 Gerhardt A, Nanakaliy D, Shah HD, Sarfaraz S, Madigan C, Downing M, Elliott RP, Dipto R, Vrapciu B, Noetzel J, Armas J, Ahmed A, Potempa M, Olson ME, **Potempa LA**, Hart PC. 2025. Evaluating the CRP Interactome: Insights into possible novel roles in cellular signaling and tumorigenicity. *Current Issues in Molecular Biology - Section of Molecular Pharmacology* 47(12):1003. <http://doi.10.3390/cimb4712003>

B. Book Chapters

May 2013 Title: ***"Head & Neck Cancer: Current Perspectives, Advances and Challenges"***

Chapter :

Mechanism of Drug Action

Authors: S Kurup PhD, KE Dineley PhD, LM Malaiyandi PhD R Adewuya MD, **LA Potempa, PhD**. Editor: JARadosevich PhD. Springer, Dordrecht Published May 2013. doi: https://doi.org/10.1007/978-94-007-5827-8_28. Print ISBN: 978-94-007-5826-1: Online ISBN978-94-007-5827-8

Oct 2018 Title: ***"Apoptosis and Beyond: The Many Ways Cells Die"***

Chapter :

• ***Alkylating agent cytotoxicity associated with O⁶-methylguanine***

Authors: LM Maliayandi PhD, **LA Potempa PhD**, N Marschalk, MS, P Jungsuwadee PhD, KE Dineley, PhD. Editor: JARadosevich PhD Vol 2, Chap 21. ISBN: 978-1-119-43243-2 <http://DOI:10.1002/9781119432463.ch21>

Mar 2020 Title: ***"Vertebrate and Invertebrate Respiratory Proteins, Lipoproteins and other Body Fluid Proteins. Subcellular Biochemistry"***

Chapter:

• ***C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond***

Authors: McFadyen JD, Zeller J, **Potempa LA**, Pietersz GA, Eisenhardt SU, Peter K. Editors: Hoeger U, Harris J. Vol 94. Springer, Cham.
http://doi:10.1007/978-3-030-41769-7_20

Jan 2022 Title: **“Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins”**

Topic editors: Daigo K, Bottazzi B, Gomer RH. Lausanne: Frontiers Media SA.

Chapters:

- **How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression**

Authors: Rajab IM, Hart PC, **Potempa LA**

- **C-reactive protein and cancer – diagnostic and therapeutic insights.**

Authors: Hart PC, Rajab IM, Alebraheem M, **Potempa LA**

<http://doi:10.3389/978-2-88974-189-2>

April 2023 Title: **“Lipids and Inflammation in Health and Disease Volume II”**

Topic Editors : Bukrinsky M, Orekhov AN, Baig MS, Myasodovas V, Ravani A, Sukhorukov V, Zhang D.

EBook – Frontiers Cardiovascular Medicine April 2023

<https://www.frontiersin.org/research-topics/39966/lipids-and-inflammation-in-health-and-disease-volume-ii>

Chapter:

- **Relevance of lipoproteins, membranes, and extracellular vesicles in understanding C-reactive protein (CRP) biochemical structure and biological activities.**

Authors: **Potempa LA**, Qiu WQ, Stefanski A, Rajab IM.

January 2026 Title: **“Community Series in Biology of C-reactive protein - Volume II”**

Topic Editors: Alok Agrawal and Yi Wu

EBook Frontiers in Immunology January 2026

<https://www.frontiersin.org/research-topics/64280/community-series-in-biology-of-creative-protein-volume-ii/magazine>

Chapter:

- **Potempa M, Hart PC, Rajab IM, Potempa LA. 2025. Redefining CRP in Tissue Injury and Repair: More Than an Acute Pro-inflammatory Mediator.**

C. Abstracts/Poster Presentations

- 1 Galsky AG, Gilbert ML, Miller J, **Potempa LA**. 1972. Characteristics of the induction of acid phosphatase in barley endosperm tissue, isocitrate lyase in hazel seeds by cyclic-AMP. Plant Phys.49:Suppl:31a

- 2 **Potempa LA**, Galsky AG. 1973. Studies on the induction of isocitrate lyase in hazel seeds by GA3 and cyclic-AMP. *Plant Physio.* 51:Suppl:4a
- 3 Garvin JE, **Potempa LA**, Marton LSG. 1975. Interconvertability of the two forms of the major human erythrocyte glycoprotein in SDS. *Jour. of Cell Biol.* 67:130a
- 4 Marder RJ, **Potempa LA**, Toriumi D, Gewurz H. 1979. Affinity chromatography purification of low molecular weight (7S) C1q precipitins from patients with hypocomplementemic vasculitis urticarial syndrome (HVUS). *Fed. Proc.* 38:146a
- 5 **Potempa LA**, James KK, Gewurz H. 1980. Amyloid-related protein in the affinity isolation of C-reactive protein. *Fed. Proc.* 39:2180A
- 6 Marder R, Toriumi D, **Potempa LA**, Gewurz H. 1980. Studies on patients with hypocomplementemic vasculitis urticarial syndrome: purification and characterization of the low molecular weight 7S C1q precipitin. *Rush University Sigma Xi Research Symposium* 29a
- 7 Fiedel BA, Frenzke ME, **Potempa LA**, Simpson RM, Gewurz H. 1980. C-reactive protein and platelet activation: The role of an accessory factor. *Clin. Res.* 28:768a
- 8 **Potempa LA**, Gewurz H. 1981. C-reactive protein binding reactivity for polycations. The modulatory role of calcium and phosphocholine. *Fed. Proc.* 40:4649a
- 9 Marder RJ, Ariano J, Jones JV, **Potempa LA**, Gewurz H. 1981. Use of C1q coated polystyrene beads for immune complex radioimmunoassay (RIA) and isolation and purification of 7S C1q precipitins (C1q-p). *Fed. Proc.* 40:5188a
- 10 Maldonado BA, Gewurz H, **Potempa LA**. 1981. Physical-chemical properties of C-reactive protein: The role of calcium ion in general protein structure. *Rush University Sigma Xi Research Symposium Abs.* # 57
- 11 AbuShmeis W, Gewurz H, Mold C, **Potempa LA**. 1981. Polycation binding reactivity of the phosphorylcholine-binding mouse myeloma HOPC-8. *Rush University Sigma Xi Research Symposium. Abs.* # 55
- 12 Fairbanks T, Gewurz H, **Potempa LA**. 1982. C-reactive protein (CRP) binding selectivity for polycations: Inhibition of precipitation reactivity by oligocations. *Fed. Proc.* 41:1676a.; and *Rush University Sigma Xi Research Symposium Abs.* #56
- 13 Fairbanks T, Gewurz H, **Potempa LA**. 1982. Binding selectivity of C-reactive protein for polycations: effect of oligocations as measured by nephelometry. *American J. Med. Tech.* 48:411a
- 14 **Potempa LA**, Maldonado BA, Gewurz H. 1982. Physical-chemical properties of C-reactive protein: A role for calcium ion in general protein structure. *Fed.Proc.* 41:1675a

- 15 Fairbanks TR, Gewurz H, **Potempa LA**. 1983. pH-induced alterations in the antigenic and binding properties of C-reactive protein (CRP). Fed. Proc. 42:2390a; and Rush University Sigma Xi Research Symposium. Abs. #16
- 16 Maldonado BA, Fairbanks T, Gewurz H, **Potempa LA**. 1983. Calcium in C-reactive protein (CRP) resistance to denaturation: CRP as a metalloprotein. Fed. Proc. 42:3921a; and Rush University Sigma Xi Research Symposium Abs. #20
- 17 **Potempa LA**, Maldonado BA, Kubak BM, Laurent P, Gewurz H. 1983. Calcium involvement in the electrophoretic and chromatographic properties of C-reactive protein (CRP). Fed. Proc. 42:3920a; & Rush Univ. Sigma Xi Research Symposium Abs. # 19
- 18 Osika CJ, **Potempa LA**, Mold C, Gewurz H. 1983. Complement activation involving surface interactions of C-reactive protein and polycations. Fed. Proc. 42:3920a; and Rush University Sigma Xi Research Symposium Abs. # 18
- 19 Zemel ES, **Potempa LA**, Gewurz H. 1983. Characterization of a new C1-like activity associated with C-reactive protein (CRP) Fed. Proc. 42:5528a
- 20 Gewurz H, **Potempa LA**, Laurent P, Baum L, Zeller J, Mold C. 1983. Immunobiology of C-reactive protein and the acute phase proteins. Proc. Symposium Sur Les Marques de L'Inflammation, Lyon, France, pg. 34
- 21 Mantzouranis EC, Goldberger G, **Potempa LA**, Whitehead AS, Gewurz H, Colten HR. 1984. Biosynthesis and postsynthetic assembly of human C-reactive protein (CRP). Ped. Res. 18:260a
- 22 Kubak B, **Potempa LA**, Gewurz H, Mahklouf S, Venegas M, Anderson B. 1984. Serum amyloid P-component calcium-dependent binding to glycoproteins, glycoconjugates and yeast extracts. The Society for Complex Carbohydrates: Abs. #63
- 23 **Potempa LA**, Pleskach KM, Potempa RPT, Gewurz H. 1985. Characteristics of a form of C-reactive protein (neo-CRP) expressing a unique neoantigenic determinant (nCRP). Fed Proc. 44:1190a
- 24 Richmond GW, Gewurz H, **Potempa LA**. 1985. Preferential reactivity of IgG C1q-precipitins with bound C1q in hypocomplementemic urticarial vasculitis syndrome (HVUS). Clin Res. 33:797a
- 25 Kubak B, **Potempa LA**, Mahklouf S, Venegas M, Anderson B, Gewurz H. 1985. Mannose and anionic polysaccharides as ligands for the serum amyloid P component. Federation Proceedings 44(4) A1189.
- 26 Chudwin DS, Artrip SG, Gewurz H, **Potempa LA**. 1986. Protective effects of an antigenically distinct form of C-reactive protein (CRP) in Pneumococcal bacteremia. J. Allergy Clin. Immunol. 77:216a
- 27 Potempa RT, Richmond GW, Thonar E, Gewurz H, **Potempa LA**. 1986. Identification and quantification of a neo-antigen of C-reactive protein (neo-CRP) in inflammatory disease. J. Allergy Clin. Immunol. 77:135a

- 28 Rees R, Gewurz H, Siegel JN, **Potempa LA**. 1986. An immunohistochemical study of the in vivo expression of a C-reactive protein neoantigen (neo-CRP) in the rabbit. Fed. Proc. 45:263a
- 29 Samberg NL, Bray RA, Landay AL, Siegel J, Gewurz H, **Potempa LA**. 1986. The expression of a neo-antigenic specificity of C-reactive protein (CRP) on the surface of peripheral blood mononuclear cells (PBMC). Fed. Proc. 45:262a
- 30 **Potempa LA**, Gewurz H. 1986. A possible role for C-reactive protein in inflammatory disease. Midwest Connective Tissue Workshop. Rush University and Medical College, Chicago, IL
- 31 Samberg NL, Bray RA, Landay AL, **Potempa LA**, Gewurz H. 1986. Identification of two distinct populations of peripheral blood lymphocytes reactive with anti-C-reactive protein reagents. Midwest Immunology Conference, Chicago, IL
- 32 Gewurz H, Siegel JN, Zeller JM, Landay AL, Chudwin D, Fiedel BA, Mold C, Anderson B, **Potempa LA**. 1986. Ligands and biological reactivities of C-reactive protein (CRP) and serum amyloid P component (SAP). Proc. XXXIVth Colloquium Protides of the Biological Fluids, Brussels, Belgium, # 005
- 33 Landay A, Samberg N, Bray R, Gewurz H, **Potempa LA**. 1986. The differential expression of native and neo-antigenic determinants of C-reactive protein on human cultured cell lines. Proc. XXXIVth Colloquium Protides of the Biological Fluids, Brussels, Belgium, #B3.23
- 34 Zeller JM, **Potempa LA**, Gewurz H. 1987. Enhancement of phagocytic cell chemiluminescence (CL) activities by forms of C-reactive protein (CRP) expressing a neoantigenic epitope. Fed. Proc. 46: 1033a
- 35 Chu EB, **Potempa LA**, Harris JE, Gewurz H, Braun DP. 1987. Modulation of monocyte cytotoxicity with urea-chelated and acid-modified C-reactive protein (CRP). Proc. Am. Acad. Cancer Res. 28:344a
- 36 Samberg NL, Bray RA, Gewurz H, **Potempa LA**, Landay AL. 1987. Antibodies to the neoantigenic but not the native-antigenic form of human C-reactive protein are reactive with normal peripheral blood lymphocytes. J. Leukocyte Biol.42:350a
- 37 Bray RA, Samberg NL, Gewurz H, **Potempa LA**, Landay AL. 1987. Human peripheral blood natural killer (NK) cells and B lymphocytes share a common determinant recognized by antibodies against a novel form of C-reactive protein (CRP). J. Leukocyte Biol. 42:379a
- 38 Bray RA, Samberg NL, **Potempa LA**, Gewurz H, Landay AL. 1987. Preferential expression of CRP neoantigen on cells of patients with clonal expansions of B cells and LGLs. Clin. Res. 35:895a
- 39 Gewurz AT, Kubak BM, **Potempa LA**, Anderson B, Gewurz H. 1987. Binding of serum amyloid P-component to zymosan involves a (phospho)-mannose oligosaccharide-containing ligand. Clin. Res. 35:895a

-
- 40 Landay AL, Gewurz H, **Potempa LA**, Samberg NL, Bray RA. 1988. Functional relationship of a novel antigenic specificity of CRP with Fc γ RIII on NK cells. NK Society Symposium
 - 41 Gupta RC, **Potempa LA**, Krishnan MR, Postlethwaite AE. 1988. C-reactive protein induces endothelial cell proliferation and biosynthesis of proteins. *Arthritis & Rheumatism* 31:R39a
 - 42 **Potempa LA**, Frank BL, Gewurz H, Zeller JM. 1988. Expression of C-reactive protein (CRP) antigenicity on the surface of human monocytes and neutrophils. *FASEB J.* 2:731a
 - 43 Chu EB, **Potempa LA**, Harris JE, Gewurz H, Braun DP. 1988. Reversal of neo-C-reactive protein mediated suppression of monocyte cytotoxicity by modulation of arachidonate metabolism. *Proc. Amer. Acad. Cancer Res.* 29:371a
 - 44 Kinoshita CM, Siegel JN, **Potempa LA**, Gewurz H. 1988. The effect of calcium-inhibited partial proteolysis of human C-reactive protein on calcium-dependent binding activity. *FASEB J.* 2:1149a
 - 45 Chu, EB, **Potempa LA**, Gewurz H, Harris JE, Braun DP. 1989. Modulation of the development of tumoricidal function in response to macrophage activators by a modified form of C-reactive protein. *Proc. Am. Acad. Cancer Res.* 30:333a
 - 46 **Potempa LA**, Jokinen DM, Anderson BE. 1990. Immunoabsorption using a modified form of C-reactive protein. *Int'l Congress on Membranes and Membrane Processes*, Chicago, Illinois
 - 47 Harris D, Lurie A, **Potempa L**, Gewurz A, Gewurz H. 1990. Aggregated human gamma globulin binds to modified C-reactive protein. *Midwest Autumn Immunology Conference*, Chicago, IL
 - 48 Anderson B, Baumann M, **Potempa L**. 1991. A C1q peptide and a modified form of C-reactive protein (mCRP) that bind immune complexes. *J. Cellular Biochemistry* 15E:170a
 - 49 **Potempa LA**, Motie M, Klein E, Anderson B. 1991. Affinity membranes for the removal of immune complexes. *Artificial Organs* 15:339a
 - 50 Anderson B, Siegel JN, Clark CR, Hines KK, **Potempa LA**, Gewurz H, Shields MJ. 1991. Quantitation and conformational changes of human C-reactive protein (CRP) and modified form (m-CRP) determined by enzyme-linked immuno-sorbent (ELISA) and enzyme-linked immunoflow (ELIFA) assays. *FASEB J.* 5:622a
 - 51 Kresl J, **Potempa LA**, Anderson B. 1991. Irreversible conversion of native oligomeric to modified form(s) of human C-reactive protein. *FASEB J.* 5:633a
 - 52 Murphy R, Wyand MS, **Potempa LA**. 1992. Antiretroviral activity and immunologic response of modified C-reactive protein in the SIV-infected monkey. *Int'l Conference AIDS* 8(3):30 (Abs. No: PuA 6114)
-

-
- 53 Kresl JJ, Meyer NA, **Potempa LA**, Chi CW, Anderson B, Radosevich JA. 1992. In vivo evidence that a modified form of human C-reactive protein is an effective agent which suppresses the growth rate of mouse mammary cell line EMT6 breast cancer. Clin Research 40 (3):691a
- 54 **Potempa LA**, Motie M, Crump BL, Schaul KW, Mehta N, Kolb K, Clatch RJ. 1996. Natural expression of neo-C reactive protein (neo-CRP) epitopes in permeabilized PBLs. FASEB J. 10:1332a
- 55 Radosevich JA, Haines GK, Motie M, Schaul KW, Mehta N, Kolb K, **Potempa LA**. 1996. Immunohistochemical detection of epitopes expressed on CRP and modified-CRP (i.e. neo-CRP) in human normal and diseased tissues. FASEB J 10:1466a
- 56 Motie M, Schaul KW, **Potempa LA**. 1996. Comparison of pharmacokinetic and biodistribution parameters of intravenously injected C-reactive protein (CRP) and modified-CRP (mCRP) in mice. FASEB J. 10:1231a
- 57 Crump BL, Burlingame RP, Sanchez Riera F, Langly KM, Schaul KE, Motie M, Kolb KM, **Potempa LA**. 1996. Expression of mutant human C-reactive protein in *E. coli*. FASEB J 10: 1124a
- 58 Crump BL, Burlingame RP, Sanchez Riera F, Langly KM, Schaul KE, Motie M, Kolb KM, **Potempa LA**. 1996. Bacterial expression of mutant human C-reactive protein. Annual meeting of the Society for Industrial Microbiology, Research Triangle Park, North Carolina, Aug 3-9, 1996
- 59 Kabat W, **Potempa LA**, Motie M, Dennis E, Yogev R. 1996. Anti-retroviral activity of a recombinant modified C-reactive protein. 21st Annual AIDS Clinical Trial Group Meeting, Washington DC, July 1996, Abstract #14
- 60 **Potempa LA**, Murphy R, Radosevich JA, Anderson B, Kresl JJ, Chan B. 1996. Biological activity and clinical safety of human modified C-reactive protein, an active new agent against cancer. Third Hong Kong International Cancer Congress & 7th International EBV Symposium. November 13-16, 1996; Abstract H 41.1
- 61 **Potempa LA**, Motie M, Murphy R, Kabat W, Yogev R, Radosevich JA, Vaith P, Chan B. 1996. In vitro studies of recombinant human modified C-reactive protein, an active new agent against HIV disease. Hong Kong AIDS Conference 1996, November 8-9, 1996, Abstract B-01
- 62 **Potempa LA**, Murphy R, Motie M, Crump B, Schaul K, Chan B. 1996. Phase I/II clinical trial of recombinant human modified C reactive protein, an active new agent against HIV disease. Hong Kong AIDS Conference 1996, November 8-9, 1996, Abstract B-02
- 63 Schneider GP, **Potempa LA**, Webster RO. 1998. Effect of altered C-reactive protein on neutrophil chemotaxis. FASEB J. 12(4):185a
- 64 Diehl EE, Radosevich JA, Haines III GK, Yokoo H, **Potempa LA**. 1998. Effect of the modified form of C-reactive protein on human tumor cells. Cancer Res AMFR
-

-
- 65 Motie M, Schaul KW, **Potempa LA**. 1998. Biodistribution and clearance of I¹²⁵-labeled C-reactive protein and I-125-labeled modified C-reactive protein in CD-1 mice. Meeting of the American-Society-of-Biochemistry-and-Molecular-Biology. Drug Metabolism and Disposition: the Biological Fate of Chemicals
- 66 Bareika A, Williams JM, Lenz ME, **Potempa L**, Thonar EJ-MA. 1999. Changes in C-reactive protein levels in rabbit sera following intraarticular injection of chymopapain. Orthopaedic Res Soc. Feb1-4
- 67 Stein M, **Potempa LA**, Vaith P, Melchers. 1999. Analyzing the binding specificity of monomeric C-reactive protein (mCRP) by screening a phage display library. Immunobiology Hannover 1999, Abs V.15
- 68 Bareika A, Williams J, Lenz M, **Potempa L**, Thonar EJ-MA. 2000. Changes in C-reactive protein levels prognosticate destruction of articular cartilage following intra-articular injection of chymopapain. Orthopaedic Res Soc 25:1004
- 69 Heuertz RM, Tricoli S, **Potempa LA**, Webster RO. 2000. Effects of different forms of C-reactive protein on human neutrophil movement and p38 MAP kinase phosphorylation. American Thoracic Soc
- 70 Stein M, **Potempa LA**, Vaith P, Melchers I. 2000. Binding of monomeric C-reactive protein (mCRP) to fibronectin is inhibited by distinct peptides. Immunobiology Hannover 2000, Abs V
- 71 Filep JG, Zouki C, Haas B, Chan JSD, **Potempa LA**. 2001. Monomeric C-reactive protein activates human neutrophils and promotes their adhesion to human coronary artery endothelial cells HCAEC. Arteriosclerosis, Thrombosis and Vascular Biology 21(4) 708
- 72 Filep JG, Zouki C, Haas B, Chan JSC, **Potempa LA**. 2001. Opposite regulation of leukocyte-endothelial cell adhesion by native and conformationally altered C-reactive protein. Canadian Cardiovascular Congress; Can J Cardiol 17 (supp C):164C
- 73 Filep JG, Zouki C, Haas B, Chan JSC, **Potempa LA**. 2002. Loss of pentameric symmetry of C-reactive protein (CRP) is associated with promotion of neutrophil-endothelial cell adhesion. New Developments in Vascular Biology and Inflammation EB2002 http://asip.uthscsa.edu/ANNMEET_COURSE/vascular.html
- 74 Schwedler SB, Guderian F, Daemrich J, **Potempa LA**, Wanner C. 2003 Tubular staining of modified c-reactive protein increases with severity of diabetic nephropathy. European Renal Association annual meeting
- 75 Oroszlán M, Herczenik E, Cervenak L, Prohászka Z, **Potempa LA**, Karádi I, Romics L, Füst G. 2003 Comparative study of native and modified forms of C-reactive protein using endothelial cells. 15th European Immunology Conference
- 76 Khreiss T, József L, **Potempa LA**, Filep JG. 2004 Opposing Effects of C-reactive Protein Isoforms on Shear-induced Neutrophil-Platelet Adhesion and Neutrophil Aggregation in Whole Blood. American Heart Association Meeting
-

-
- 77 Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, **Potempa LA**, Galle J. 2004 Native C-reactive protein (CRP) increases, whereas modified CRP reduces atherosclerosis in apoE-knockout mice. J Amer Soc of Nephrology 15:407A
- 78 Allen JL, Fitzpatrick K, John BA, Townley SJ, McGowan A, Akhurst LC, **Potempa LA**, Bongard E, Vivas L. 2005 Selective accumulation of DB75 in *P. falciparum*-infected Human Erythrocytes *in vitro*. Int'l. Congress Trop Med (Fall Meeting 2005) A:420.
- 79 Schwedler SB, Amann K, Wernicke K, Wanner C, **Potempa LA**, Galle J. 2005 Native and modified C-reactive protein (CRP) exert different effects on inflammatory mediators in Apo E^{-/-} mice. J Amer Soc of Nephrology 2005 meeting
- 80 Khreiss T, József L, **Potempa LA**, Filep JG. 2005 C-reactive protein induces Interleukin-8 Production through peroxynitrite signaling in human neutrophils. Circulation Abstract Supplement :14583A - American Heart Association Meeting (Dallas, TX)
- 81 Fercu D, **Potempa LA**. 2006 Evaluating Chem/Bio Discovery Informatics Software for Small Pharma with Academic Collaborators. Cambridge Healthcare Institute World Pharmaceutical Congress . Philadelphia, PA 2006 meeting
- 82 Schwedler SB, **Potempa LA**, Wanner C, Galle J, Hansen-Hagge TE. 2006 Modified C-reactive protein decreases cellular uptake of modified low-density lipoprotein (LDL) but does not modulate oxidative stress in human endothelial cells. J Amer Soc of Nephrology 2006 meeting
- 83 Ji SR, Wu Y, **Potempa LA**, Zhu L, Lang YH, Quip Q, Zhao J. 2007 Structural transition from pentamer to monomer: A mechanism that finely regulates C-reactive protein's reactivity and behavior in the inflammatory [process of atherosclerosis. Am Heart Assoc. Athero Thromb Vasc Biol Annual Meeting. P524
- 84 Filep JG, Khreiss T, József L, **Potempa LA**, El Kebir D. 2007. Does C-Reactive Protein Orchestrate Inflammation in Acute Coronary Artery Disease? 13th World Congress on Heart Disease, Vancouver, BC, Canada. July 28-31: Abs # 130
- 85 Reichert M, **Potempa LA**, Wanner C, Galle J, Hansen-Hagge TE, Schwedler SB. 2007. Monomeric C-reactive protein (mCRP) decreases uptake of modified low-density lipoprotein (LDL) in endothelial cells: Role of CD16 and CD32. Univ of Wursburg Research Symposium
- 86 Boncler M, Rywaniak J, **Potempa LA**, Rychlik B, Rysz J, Watala C. 2008. Distinct Effects of C-reactive protein isoforms on platelet function. Congress of Biochemistry and Cell Biology, Sept 7-1, 2008
- 87 Slevin M, Turu MM, Badimon I, **Potempa LA**, Wu Y, Mitsios N, Matou S, Luque A, Krupinski J. 2008. Modified C-reactive protein is predominantly expressed in the neovessels of complicated atherosclerotic plaques and is potently angiogenic *in vitro*. 17th European Stroke Conference, Nice, France. Cerebrovascular Disease 25:Vascular Biology Pg 155, Abs #8
-

-
- 88 Ji S-R, **Potempa LA**, Filep JG, Wu Y. 2009. Reduction of the intra-subunit disulfide bond activates monomeric C-reactive protein to stimulate endothelial cells via interaction with lipid raft domains. International Symposium on Atherosclerosis meeting. Abs # 50030
- 89 Slevin M, Rovina N, Turu M, Luque L, Badimon L, Gaffney J, **Potempa LA**, Krupinski J. 2009. Modified CRP is expressed in in adventitia and intimal neovessels from complicated regions of unstable carotid plaques Neovessels and Is a Potent Activator of Angiogenesis In Vitro. 18th European Stroke Conference
- 90 Schwedler SB, Kuhlencordt PJ, Padmapriya Ponnuswamy P, Hatiboglu G, Potempa LA, Galle J. 2009. Implications for iNOS and reactive oxygen species Short title: C-reactive protein, iNOS and oxidative stress. . J Amer Soc of Nephrology 2009 meeting
- 91 Hammond DJ, Singh SK, Pangburn MK, **Potempa LA**, Agrawal A. 2010. Requirement of acidic pH for the binding of pentameric C-reactive protein to factor H. International Complement Workshop – New York, August
- 92 Ji S-R, Wang M-Y, Li HY, **Potempa LA**, Filep JG, Zhao J, Wu Y. 2010. C-reactive protein as a link between inflammation and atherosclerosis. Australian Vascular Biology Society 18th National Scientific Conference, September 2010
- 93 Ji S-R, Wang M-Y, Bai C-J, **Potempa LA**, Filep JG, Wu Y. 2012 Sequential conformation changes in C-reactive protein are required to activate endothelial cells. European Atherosclerosis Society Congress (EAS); Milan, Italy on May 25-28, 2012
- 94 Kurup S, **Potempa LA**. 2012. Using Molecular Modeling to Integrate Biochemistry and Medicinal Chemistry in a Pharmacy Curriculum. Amer Asso College of Pharmacy Annual Meeting
- 95 Boras EA, Matou-Nasri S, Kuprinski J, **Potempa LA**, Badimon L, Slevin M. 2012 Common Angiogenic Signalling Pathways Induced by Monomeric c-Reactive Protein and FGF-2 Through Phosphatidylinositol 3-kinase. International Stroke Conference Oral Abstracts. Session: Aneurysm and vascular malformations. Stroke 43:A181. https://doi.org/10.1161/str.43.suppl_1.A181
- 96 Chauhan BC, **Potempa LA**, Davis FJ, Chauhan NB. 2013. Natural Expression of C-reactive protein and its isoforms in a mouse model of Alzheimer's disease. Am Assoc College Pharmacy annual meeting
- 97 Myint AY, **Potempa LA**, Berghmans R. 2014. Advantages of mCRP over pCRP in diagnosis of autoimmune diseases. Immunology Summit, Baltimore, September 2014 Abstract
- 98 Chirco KR, Flamme-Wiese MJ, Andorf JL, Johnston RM, **Potempa LA**, Riker MJ, Workalemahu G, Stone EM, Tucker BA, Mullins RF. 2015. Monomeric C-reactive protein (mCRP) in human donor choroids: relationship with CFH genotype and effects on endothelial cell function. ARVO (Association for Research in Vision & Ophthalmology), Denver, CO. May 2015
-

- 99 Munuswamy R, Berghmans R, Myint AM, Michiels L, Halaris A, **Potempa L**. 2015. Is monomeric CRP a marker for development of CRP in patients with MDD? Symposium :The immune-brain axis: from molecules to behavior. University of Hasselt, Belgium 12-13 Mar 2015. The immune-brain axis: from molecules to behaviour conference.
- 100 Boras E, Slevin M, Alexander MY, Aljohi A, Gilmore W, Ashworth J, Krupinski J, **Potempa LA**, Al Abdulkareem I, Elobeid A, Matou-Nasri S. 2015. Monomeric C-reactive Protein-Induced Angiogenesis Requires Gamma-Secretase Activity, Operates Through the PI3K/Akt Pathway and May Potentiate Notch-3 Function In Promotion Of Blood Vessel Stability. International Stroke Conference
- 101 Slevin M, Matou S, Zeinolabediny Y, Corpas R, Weston R, Di Napoli M, Petcu E, Sarroca S, Popa-Wagner A, Love S, Font MA, **Potempa LA**, Al-Baradie R, Sanfeliu C, Revilla S, Badimon L, Krupinski J. 2015. Monomeric C-reactive protein-a key molecule driving development of Alzheimer's disease associated with brain ischaemia? The European Stroke Research Organisation Conference ESOC Glasgow Scotland UK. April 2015
- 102 Boras E, Slevin M, Gilmore W, **Potempa LA**, Matou-Nasri S. 2015. Common angiogenic signalling pathways induced by monomeric-CRP and FGF-2 through PI3K pathway. 6th KAIMRC Annual Scientific Forum. King Saud Bin Abdulaziz University for Health Sciences, Riyadh 14611, Saudi Arabia 9-10 of DEC 2015
<http://kaimrcforum.org/>
- 103 Chirco KR, Whitmore SS, Zeng S, Workalemahu G, **Potempa LA**, Miller SE, Stone EM, Tucker BA, Mullins RF. 2016. Monomeric C-reactive protein and altered human endothelial cell function in age-related macular degeneration. ARVO (Association for Research in Vision & Ophthalmology), Orlando, FL. May 2016
- 104 Thiele JR, Zeller J, Kiefer K, Braig D, Eisenhardt SU, **Potempa LA**, Peter K. 2018. A Conformational Change in C-Reactive Protein Enhances Leukocyte Recruitment and Reactive Oxygen Species Generation in Ischemia/Reperfusion Injury. Cardiology Conference
- 105 Svanberg C, Enocsson H, Martinsson K, **Potempa LA**, Rajab I, Jonas Wetterö J, Larsson M, Sjowall C. 2019. Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis. American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting, Atlanta, GA, November 8–13, 2019 (Oral presentation). Abstract 2813.
- 106 Svanberg C, Enocsson H, Martinssonm K, **Potempa LA**, Rajab I, Jonas Wetterö J, Larsson M, Sjowall C. 2020. Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis. Lupus Science & Medicine 7(Suppl 1) A1-A131 P106. 12th European Lupus meeting. March. <http://doi10.1136/lupus-2022-eurolupus.150>

- 107 Ruiz-Fernández C, González-Rodríguez M, Francisco V, Rajab IM, Gómez Bahamonde R, Aranda JC, Lago F, Pino J, Mobasher A, González-Gay MA, Varela AM, **Potempa LA**, Gualillo O. 2021. Monomeric C Reactive Protein (mCRP) Regulates Inflammatory Responses in Human and Mouse Chondrocytes. EULAR 2021 CONGRESS Abstract No. 4290. <http://doi10.1136/annrheumdis-2021-eular.4290>
- 108 Ruiz-Fernández C, González-Rodríguez M, Francisco V, Rajab IM, Gómez Bahamonde R, Aranda JC, Lago F, Pino J, Mobasher A, González-Gay MA, Varela AM, **Potempa LA**, Gualillo O. 2021. Monomeric C Reactive Protein (mCRP) Regulates Inflammatory Responses in Human and Mouse Chondrocytes. *Annals of the Rheumatic Diseases* 80:418.
- 109 Karlsson J, Wetterö J, **Potempa LA**, Mobarrez F, Sjöwall C. 2022. Extracellular vesicles opsonized by monomeric C-reactive protein are accessible as autoantigens in systemic lupus erythematosus. 13th European Lupus Meeting. October. <http://doi:10.1136/lupus-2022-elm2022.101>
- 110 Gjoni A, Garcia A, Albanna H, **Potempa LA**, Hart PC. 2024. C-reactive protein as a biomarker and potential therapeutic in high-grade serous ovarian cancer. Illinois Pharmacists Association (IPhA) Annual Meeting Poster Competition. Springfield, IL, Sept. 28th 2024. Poster won first place in the poster competition; delivered by A. Gjoni and A. Garcia.
- 111 Gjoni A, Garcia A, Albanna H, **Potempa LA**, Hart PC. 2025. C-reactive protein as a biomarker and potential therapeutic in high-grade serous ovarian cancer. Roosevelt University Research and Discovery Showcase. Schaumburg, IL, April 4th, 2025. Poster presentation delivered by J. Noetze

C. Acknowledgements in Manuscripts using my Reagent and Concepts and Help:

- 1 Katalin Udvarnoki K, Cervenak L, Uray K, Hudecz F, Kacs Kovics I, Spallek R, Singh M, Füst G, Prohászka Z. 2007. Antibodies against C-Reactive Protein Cross-React with 60-Kilodalton Heat Shock Proteins Clin and Vaccine Immunol 14(4):335–341. <http://doi:10.1128/CVI.00155-06>
- 2 Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, Thielens NM, Arlaud GJ, Prohaszka Z. 2007. Studies on the interactions between C-reactive protein and complement proteins. *Immunology* 121:40–50. <http://doi:10.1111/j.1365-2567.2007.02535.x>
- 3 Sjöwall C, Bengtsson AA, Sturfelt G, Skogh T. 2004. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. *Arthritis Res Ther* 6:R87-R94 <http://doi:10.1186/ar1032>
- 4 Udvarnoki K, Cervenak L, Uray K, Hudecz F, Kacs Kovics I, Spallek R, Singh M, Füst G, Prohászka Z. 2007. Antibodies against C-reactive protein cross-react with 60-kilodalton heat shock proteins. *Clin Vaccine Immunol* 14(4):335-341. <http://doi:10.1128/CVI.00155-06>
- 5 Saboor-Yaraghi AA, Rodriguez JA, Meyer DM, Collins C, Maller NC, Agrawal A, Nordlund HR, Raynes JR. 2007. C-reactive protein interaction with biotin binding proteins. *FEBS J*.

- 6 Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K. 2009. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. *Cir Res*. 105:128-137. <https://doi.org/10.1161/CIRCRESAHA.108.190611>
- 7 Bergsma D, Chen S, Buchweitz J, Gerszten R, Haab BB. 2010. Antibody-array interaction mapping, a new method to detect protein complexes applied to the discovery and study of serum amyloid P interactions with kininogen in human plasma. *Mol Cell Proteomics*. 2010;9(3):446-456. <http://doi:10.1074/mcp.M900418-MCP200>
- 8 Ahrens I, Domeij H, Eisenhardt SU, Topcic D, Albrecht M, Leitner E, Viitaniemi K, Jowett JB, Lappas M, Bode C, Haviv I, Peter K. 2011. Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells. *Basic Res Cardiol* 106:879-895.
- 9 Lappas M, Bode C, Haviv I, Peter K. 2011. Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells. *Basic Res Cardiol* 106:879-895.
- 10 Habersberger J, Strang F, Scheichl A, Htun N, Bassler N, Merivirta RM, Diehl P, Krippner G, Meikle P, Eisenhardt SU, Meredith I, and Peter K. 2012. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. *Cardiovasc Res*. 96(1):64-72
- 11 Wang MS, Black JC, Knowles MK, Reed SM. 2011. C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP. *Anal Bioanal Chem* 401(4):1309-1318. <http://doi:10.1007/s00216-011-5174-1>
- 12 Wang MS, Messersmith RE, and Reed SM. 2012. Membrane curvature recognition by C-reactive protein using lipoprotein mimics. *Soft Matter*. 8(30):7909-7918.
- 13 Strang F, Scheichl A, Chen YC, Wang X, Htun NM, Bassler N, Eisenhardt SU, Habersberger J, and Peter K. 2012. Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer's disease? *Brain Pathol*. 22(3):337-346.
- 14 Eisenhardt SU, Starke J, Thiele JR, Murphy A, Björn Stark G, Bassler N, Sviridov D, Winkler K, Peter K. Pentameric CRP attenuates inflammatory effects of mmLDL by inhibiting mmLDL--monocyte interactions. *Atherosclerosis*. 2012 Oct;224(2):384-93. <http://doi:10.1016/j.atherosclerosis.2012.07.039>
- 15 de la Torre R, Pena E, Vilahur G, Slevin M, and Badimon L. 2013. Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: pentraxins and platelet deposition. *J Thromb Haemost* 11(11):2048-2058.
- 16 Braig D, Kaiser B, Thiele JR, Bannasch H, Peter K, Stark GB, Koch HG, and Eisenhardt SU. 2014. A conformational change of C-reactive protein in burn wounds unmasks its proinflammatory properties. *Int Immunol* 26(8):467-478.

- 17 Shi P, Li X-X, Zhu W, Yang H, Dong C, Li X-M. 2014. Immunohistochemical staining reveals C-reactive protein existing predominantly as altered conformation forms in inflammatory lesions. *Acta Biologica Hungarica* 65(3):265–273.
<http://DOI:10.1556/ABiol.65.2014.3.3>
- 18 Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, Bannasch H, Scheichl A, Woollard KJ, von Dobschütz E, Kolodgie F, Virmani R, Stark GB, Peter K, Eisenhardt SU. 2014. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: *in vivo* proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. *Circulation* 130(1):35-50
<http://doi:10.1161/CIRCULATIONAHA.113.007124>
- 19 Thiele JR, Zeller J, Bannasch H, Stark GB, Peter K, Eisenhardt SU, 2015. Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes – Review. *Mediators of Inflammation* 2015:Article ID 37432.
<http://dx.doi.org/10.1155/2015/372432>.
- 20 Crawford JR, Trial J, Nambi V, Hoogeveen RC, Taffet GE, Entman ML. 2016. Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein Are Increased in Peripheral Artery Disease. *Journal of Cardiovascular Translational Research* 9(3):184-193. <http://Doi:10.1007/s12265-016-9678-0> On line read-only access: <https://rdcu.be/6zfw>
- 21 O'Flynn J, van der Pol P, Dixon KO, Prohászka Z, Daha MR, van Kooten C. 2016. Monomeric C-reactive protein inhibits renal cell-directed complement activation mediated by properdin. *Am J Physiol Renal Physiol* 310:F1308–F1316.
<http://doi:10.1152/ajprenal.00645.2014>
- 22 Goda T, Miyahara Y. 2017. Calcium-independent binding of human C-reactive protein to lysophosphatidylcholine in supported planar phospholipid monolayers. *Acta Biomaterialia* 48:206 – 214.
- 23 Hall NR. 2017. The effects of C-reactive protein (CRP) isoforms on inflammation and wound healing processes. PhD Dissertation. Manchester Metropolitan University, Manchester, England.
- 24 Li QY, Li HY, Fu G, Yu F, Wu Y, Zhao MH. 2017. Autoantibodies against C-Reactive Protein Influence Complement Activation and Clinical Course in Lupus Nephritis. *J Am Soc Nephrol* 28(10):3044-3054. <http://doi:10.1681/ASN.2016070735>
- 25 Wang Y-D, Ji S-R and Wu Y. 2018. An ELISA Assay for Quantifying Monomeric C-Reactive Protein in Plasma. *Front. Immunol.* 9:511.
<http://doi:10.3389/fimmu.2018.00511>
- 26 Boncler M, Kehrel B, Szewczyk R, Stec-Martyna E, Bednarek R, Brodde M, Watala C. 2018. Oxidation of C-reactive protein by hypochlorous acid leads to the formation of potent platelet activator. *International Journal of Biological Macromolecules* 107:2701–2714. <https://doi.org/10.1016/j.ijbiomac.2017.10.159>

- 27 Di Napoli M, Slevin M, Popa-Wagner A, Singh P, Lattanzi S, Divani AA. 2018. Monomeric C-Reactive Protein and Cerebral Hemorrhage: From Bench to Bedside. *Front. Immunol.* 9:1921. <http://doi:10.3389/fimmu.2018.01921>
- 28 Slevin M, Iemma RS, Zeinolabediny Y, Liu D, Ferris GR, Caprio V, Phillips N, Di Napoli M, Guo B, Zeng X, AlBaradie R, Binsaleh NK, McDowell G, Fang W-H. 2018. Acetylcholine Inhibits Monomeric C-Reactive Protein Induced Inflammation, Endothelial Cell Adhesion, and Platelet Aggregation; A Potential Therapeutic? *Front. Immunol.* 9:2124-2135. <http://doi:10.3389/fimmu.2018.02124>
- 29 Sproston NR, El Mohtadi M, Slevin M, Gilmore W, Ashworth JJ. 2018. The Effect of C-Reactive Protein Isoforms on Nitric Oxide Production by U937 Monocytes/Macrophages. *Front. Immunol.* 9:1500-1514. <http://doi:10.3389/fimmu.2018.01500>
- 30 Lv JM, Wang MY. 2018. *In vitro* generation and bioactivity evaluation of C-reactive protein intermediate. *PLoS One* 13(5):e0198375. <http://doi:10.1371/journal.pone.0198375>
- 31 Lv JM, Chen JY, Liu ZP, Yao ZY, Wu YX, Tong CS, Cheng B. 2020. Cellular Folding Determinants and Conformational Plasticity of Native C-Reactive Protein. *Front Immunol* 11:583. <http://doi:10.3389/fimmu.2020.00583>
- 32 Zeinolabediny Y, Kumar S, Slevin M. 2021. Monomeric C-Reactive Protein - A Feature of Inflammatory Disease Associated With Cardiovascular Pathophysiological Complications? *In Vivo* 35(2):693-697. <http://doi:10.21873/invivo.12309>
- 33 Al-Baradie RS, Pu S, Liu D, Zeinolabediny Y, Ferris G, Sanfeli C, Corpas R, Garcia-Lara E, Alsagaby SA, Alshehri BM, Abdel-hadi AM, Ahmad F, Moatari P, Heidari N and Slevin M. 2021. Monomeric C-Reactive Protein Localized in the Cerebral Tissue of Damaged Vascular Brain Regions Is Associated With Neuro-Inflammation and Neurodegeneration-An Immunohistochemical Study. *Front Immunol* 12:644213 <http://doi:10.3389/fimmu.2021.644213>
- 34 García-Lara E, Aguirre S, Clotet N, Sawkulycz X, Bartra C, Almenara-Fuentes L, Suñol C, Corpas R, Olah P, Tripon F, Crauciuc A, Slevin M, Sanfeliu C. 2021. Antibody Protection against Long-Term Memory Loss Induced by Monomeric C-Reactive Protein in a Mouse Model of Dementia. *Biomedicines* 9:828-251. <http://doi.org/10.3390/biomedicines9070828>
- 35 Melnikov I, Kozlov S, Saburova O, Zubkova E, Guseva O, Domogatsky S, Arefieva T, Radyukhina N, Zvereva M, Avtaeva Y, Buryachkovskaya L, Gabbasov Z. 2021. CRP Is Transported by Monocytes and Monocyte-Derived Exosomes in the Blood of Patients with Coronary Artery Disease. *Biomedicines* 19:8(10):435-445 <http://doi:10.3390/biomedicines8100435>
- 36 Fujita C, Sakurai Y, Yasuda Y, Takada Y, Huang CL, Fujita M. 2021. Anti-Monomeric C-Reactive Protein Antibody Ameliorates Arthritis and Nephritis in Mice. *J Immunol* 207(7):1755-1762 <http://doi:10.4049/jimmunol.210034>

-
- 37 Køstner AH, Nielsen PS, Georgsen JB, Parner ET, Nielsen MB, Kersten C, Steiniche T. 2021. Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer-May Cold Tumors Simply Be Too Hot? *Front Immunol.* 12:716342. <http://doi:10.3389/fimmu.2021.716342>
- 38 García-Lara E, Aguirre S, Clotet N, Sawkulycz X, Bartra C, Almenara-Fuentes L, Suñol C, Corpas R, Olah P, Tripon F, Crauciuc A, Slevin M, Sanfeliu C. 2021. Antibody Protection against Long-Term Memory Loss Induced by Monomeric C-Reactive Protein in a Mouse Model of Dementia. *Biomedicines* 9(7):828. <http://doi:10.3390/biomedicines9070828>
- 39 Enocsson, H.; Karlsson, J.; Li, H.-Y.; Wu, Y.; Kushner, I.; Wetterö, J.; Sjöwall, C. The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. *J. Clin. Med.* 2021, 10, 5837. <https://doi.org/10.3390/jcm10245837>
- 40 Slevin M, Heidari N, Azamfirei L. 2022. Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target. *Front Immunol* 13:866379. <http://doi:10.3389/fimmu.2022.866379>
- 41 Zhang Z, Gan Q, Tao Q, Wei Qiu QW, Madri JA. 2022. CD31: a probable responding and gate-keeping protein of the blood-brain axis during peripheral chronic low-grade inflammation for the risk of Alzheimer's disease *Submitted*.
- 42 Liang Y, Xu K, Liu W, Liu X, Yuan P, Xu P, Li H. 2022. Monomeric C-reactive protein level is associated with osteoarthritis. *Experimental and Therapeutic Medicine* 23 (4):277. <https://doi.org/10.3892/etm.2022.11206>
- 43 Zeller J, Bogner B, McFadyen JD, Kiefer J, Braig D, Pietersz G, Krippner G, Nero TL, Morton CJ, Shing KSCT, Parker MW, Peter K, Eisenhardt SU. 2022. Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases. *Pharmacol Ther* 235:108165. <http://doi:10.1016/j.pharmthera.2022.108165>
- 44 Ullah N, Wu Y. 2022. Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity. *Cell Biochem Biophys* <https://doi.org/10.1007/s12013-022-01089-x>
- 45 Al-Baradie RS, Abdel-Hadi A, Ahmad F, Alsagaby SA, Slevin M, Alturaiki W, Madkhali Y, Aljarallah BM, Alqahtani M, Miraj M, Ahmad I, Albaradie N, Albaradie R. 2022 Association of monomeric C-Reactive Protein (m-CRP) with hypothalamic neurons after CRP hippo-campal administration in a model of dementia. *Eur Rev Med Pharmacol Sci* 26(23):8713-8718. http://doi:10.26355/eurrev_202212_30543
- 46 Zeller J, Cheung Tung Shing KS, Nero TL, McFadyen JD, Krippner G, Bogner B, Kreuzaler S, Kiefer J, Horner VK, Braig D, Danish H, Baratchi S, Fricke M, Wang X, Kather MG, Kammerer B, Woollard KJ, Sharma P, Morton CJ, Pietersz G, Parker MW, Peter K, Eisenhardt SU. 2022. A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein. *EMBO Mol Med* Jan 11;15(1):e16236. <http://doi:10.15252/emmm.202216236>
-

-
- 47 Li HY, Gao N, Liu CY, Liu XL, Wu F, Dai N, Han J, Li QY. 2022. The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2. *Front Immunol* 13:918731. <http://doi:10.3389/fimmu.2022.918731>
- 48 Halaris A, Prochaska D, Stefanski A, Filip M. 2022. C-reactive protein in major depressive disorder. Promote and Challenge. *Journal of Affective Disorders Reports*. 10:100427. <https://doi.org/10.1016/j.jadr.2022.100427>
- 49 Melnikov I, Kozlov S, Saburova O, Avtaeva Y, Guria K, Gabbasov Z. 2023. Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives. *International Journal of Molecular Sciences* 24(3):2079. <https://doi.org/10.3390/ijms24032079>
- 50 Zhou L, Chen SJ, Chang Y, Liu SH, Zhou YF, Huang XP, Hua YX, An H, Zhang SH, Melnikov I, Gabbasov ZA, Wu Y, Ji SR. 2023. Monomeric C-reactive protein evokes TCR Signaling-dependent bystander activation of CD4+ T cells. *Mol Immunol* 157:158-166. <http://doi:10.1016/j.molimm.2023.03.025>
- 51 Ji SR, Zhang SH, Chang Y, Li HY, Wang MY, Lv JM, Zhu L, Tang PMK, Wu Y. 2023. C-Reactive Protein: The Most Familiar Stranger. *J Immunol* 210(6):699-707. <http://doi:10.4049/jimmunol.2200831>
- 52 Ullah N, Wu Y. 2022. Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity. *Cell Biochem Biophys* 80(4):595-608. <http://doi:10.1007/s12013-022-01089-x>.
- 53 Zhang Z, Gan Q, Han J, Tao Q, Qiu WQ, Madri JA. 2023. CD31 as a probable responding and gate-keeping protein of the blood-brain barrier and the risk of Alzheimer's disease. *J Cereb Blood Flow Meta* 43(7):1027-1041. <http://doi:10.1177/0271678X231170041>
- 54 Hopkins FR, Nordgren J, Fernandez-Botran R, Enocsson H, Govender M, Svanberg C, Svensson L, Hagbom M, Nilsdotter-Augustinsson Å, Nyström S, Sjöwall C, Sjöwall J, Larsson M. 2023. Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19. *Front Immunol*. 2023 Sep 1;14:1259005. <http://doi:10.3389/fimmu.2023.1259005>
- 54 Zeller J, Cheung Tung Shing KS, Nero TL, McFadyen JD, Krippner G, Bogner B, Kreuzaler S, Kiefer J, Horner VK, Braig D, Danish H, Baratchi S, Fricke M, Wang X, Kather MG, Kammerer B, Woollard KJ, Sharma P, Morton CJ, Pietersz G, Parker MW, Peter K, Eisenhardt SU. 2023. A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein. *EMBO Mol Med* 15(1):e16236. <http://doi:10.15252/emmm.202216236>
- 55 Ruiz-Fernández C, Ait Eldjoudi D, González-Rodríguez M, Cordero Barreal A, Farrag Y, García-Caballero L, Lago F, Mobasheri A, Sakai D, Pino J, Gualillo O. 2023. Monomeric CRP regulates inflammatory responses in human intervertebral disc cells. *Bone Joint Res* 12(3):189-198. <http://doi:10.1302/2046-3758.123.BJR-2022-0223.R1>
-

- 56 Halaris A, Hain D, Law R, Brown L, Lewis D, Filip M. Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression. *Brain Behav Immun Health*. 2023 Apr 20;30:100625. doi: 10.1016/j.bbih.2023.100625
- 57 Bartra C, Yuan Y, Vuraić K, Valdés-Quiroz H, Garcia-Baucells P, Slevin M, Pastorello Y, Suñol C, Sanfeliu C. 2024. Resveratrol Activates Antioxidant Protective Mechanisms in Cellular Models of Alzheimer's Disease Inflammation. *Antioxidants* 13(2):177. <http://doi:10.3390/antiox13020177>
- 58 Pastorello Y PhD thesis in the Doctoral School of Medicine and Pharmacy - George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures 2024 Titled: Monomeric C-reactive protein macrophage activation, and vascular disease pathology.
- 59 Lewis TY, Denzel Tupas K. 2024. Enhancing hypertension pharmacotherapeutics education by integrating social determinants of health. *Am J Pharm Edu* 88:100727. <https://doi.org/10.1016/j.ajpe.2024.100727>
- 60 Muresan S, Slevin M. C-reactive Protein: An Inflammatory Biomarker and a Predictor of Neurodegenerative Disease in Patients With Inflammatory Bowel Disease? *Cureus*. 2024 Apr 25;16(4):e59009. <http://doi:10.7759/cureus.59009>
- 61 Muresan S, Slevin M, Szasz E, Loghin A. Monomeric C-Reactive Protein Potential Utilization in the Histological Assessment of Inflammatory Bowel Disease (IBD) Patients. *Cureus*. 2024 Jun 26;16(6):e63200. <http://doi:10.7759/cureus.63200>
- 62 Gao N, Yuan P, Tang ZM, Lei JG, Yang ZR, Ahmed M, Yao ZY, Liang D, Wu Y, Li HY. 2024. Monomeric C-reactive protein is associated with severity and prognosis of decompensated hepatitis B cirrhosis. *Front Immunol* 15:1407768 <http://doi:10.3389/fimmu.2024.1407768>
- 63 Armas J, Noetzel J, Vrapciu B, Saucedo A, Moozhayil S, Consalvo A, Hart PC. 2024. Modulation of mitochondrial function by monomeric C-reactive protein (mCRP) in ovarian cancer. Illinois Pharmacists Association (IPhA) Annual Meeting Poster Competition. Springfield, IL, Sept. 28th 2024. Poster presentation delivered by J. Armas, J. Noetzel, and B. Vrapciu.
- 64 Abdelhalim AZ, Ebdai, L, Hart PC. 2024. Evaluation of the effects of monomeric C-reactive protein on epithelial tumor cells. Illinois Pharmacists Association (IPhA) Annual Meeting Poster Competition. Springfield, IL, Sept. 28th 2024. Poster presentation delivered by A. Abdelhalim and Leila Ebdair.
- 65 Karasu E, Halbgebauer R, Schütte L, Greven J, Bläsius FM, Zeller J, Winninger O, Braig D, Messerer DAC, Berger B, Feuerstein H, Schultze A, Peter K, Knippschild U, Horst K, Hildebrand F, Eisenhardt SU, Huber-Lang M. 2025. A conformational change of C-reactive protein drives neutrophil extracellular trap formation in inflammation. *BMC Biol*. 2025 Jan 7;23(1):4. <http://doi:10.1186/s12915-024-02093-8>

- 66 Shah HD, Sarfaraz S, Hart, PC. 2025. Monomeric C-reactive protein (mCRP) promotes chemoresistance to carboplatin in ovarian cancer. Roosevelt University Research and Inquiry Symposium. Chicago, IL, April 11th, 2025. Poster presentation delivered by H.D. Shah.
- 67 Noetzel J, Armas J, Vrapciu B, Hart PC. 2025. Potential modulation of mitochondrial function by monomeric C-reactive protein in ovarian cancer. Roosevelt University Research and Discovery Showcase. Schaumburg, IL, April 4th, 2025. Oral presentation delivered by J. Noetzel.
- 68 Noetzel J, Armas J, Vrapciu B, Hart PC. 2025. Potential modulation of mitochondrial function by monomeric C-reactive protein in ovarian cancer. Roosevelt University Research and Discovery Showcase. Schaumburg, IL, April 4th, 2025. Poster presentation by J. Armas and B. Vrapciu.

This list is continually being updated

FILED and ISSUED PATENTS as INVENTOR

1. **Binding of immune complexes by modified forms of C-reactive protein**
U.S. application Serial No. 08/271,137 (a CIP of 07/582,884 filed 03 Oct 90)
Filed: 06 July 94 as co-inventor with B. Anderson
Issued: 5,593,897 14 Jan 1997
- Also filed internationally
2. **Method of treating non-Streptococcal bacterial infections**
U.S. application No. 07/800,508; Filed: 27 November 1991
Issued: 5,405,832 11 Apr 1995
- Also filed internationally
3. **Method of Treating Viral (HIV) Infections**
Filed: 7 September 1993; Ser No. 08/117,874
Issued: 5,585,349 17 Dec 1996
- Also filed internationally
4. **Method for Treating Viral Infection (Continuation-in-Part)**
Filed December 17, 1996; Serial Number 08/767,795
Issued: 5,585,349 17 Dec 1996
Issued: 6,239,099 B1 29 May 2001
- Also filed internationally
5. **Monoclonal antibodies to C-reactive protein**
Filed 29 June 89; Ser No. 07/374,166
Filed as co-inventor with J. Siegel and H. Gewurz
Issued: 5,272,258 21 Dec 1993
- Also filed internationally

6. **Methods of treating cancer using modified-CRP**
Filed 24 Apr 1992; Ser No. 07/874,26
Filed as co-inventor with J. Kresl and B. Anderson
Issued: 5,283,238 01 Feb 1994
- Also filed internationally
7. **Method of imaging cancer cells using modified C-reactive protein**
Filed 9 Nov 1993; Ser No: 08/149,663
U.S. application filed as co-inventor with J Kresl and B Anderson
Issued: 5,474,904 12 Dec 1995
- Also filed internationally

Aka: Composition for Detecting Cancer Cells by Using Modified C-reactive protein
Austrian application filed as co-inventor with JJ Kresl and BE Anderson
Issued: AT232395T 2 Feb 2003
8. **A mutant protein and methods and materials for making and using it**
Filed 07 Jun 1995; Serial No: 08/480,270
Filed as co-inventor with H Liao and BL Crump
Issued: 5,874,238 23 Feb 1999
- Also filed internationally
9. **A mutant protein and methods and materials for making and using it**
Divisional application focused on treating cancer
Filed: 16 Dec 1998; Serial No. 09/212,850,
As co-inventor with H Liao and BL Crump
- Also filed internationally
10. **A mutant protein and methods and materials for making and using it**
Divisional application focused on treating cancer
Filed: 22 March 1999; Serial No. 09/273,397
As co-inventor with H Liao and BL Crump
- Also filed internationally
11. **A mutant protein and methods and materials for making and using it**
Divisional application focused on treating cancer
Filed 22 March 1999; Serial No. 09/274,454
As co-inventor with H Liao and B L Crump
Issued 6,703,219 B1 9 Mar 2004
- Also filed internationally
12. **Methods and kits for stimulating production of megakaryocytes and thrombocytes**
Filed 23 February 1994; Serial No. 08/202,033
Issued: 5,547,931 20 Aug 1996
- Also filed internationally
13. **Methods and kits for stimulating production of megakaryocytes and thrombocytes (using recombinant mCRP)**
U.S. Continuation-in-part Application
Filed 27 October 1995; Serial No: 08/549,013
Issued: 6,051,415 18 Apr 2000
- Also filed internationally

14. **Methods and kits for stimulating production of megakaryocytes and thrombocytes (articles and manufacturing kits)**
U.S. Continuation-in-part Application
Filed 27 October 1995; Serial Number 08/548,974
Issued: 5,939,529 17 Aug 1999
- Also filed internationally
15. **Use of mCRP for delivery of materials into cells**
U.S. Continuation-in-part Application
Filed as coinvestigator with JA Radosevich and EE Diehl
Filed: 18 August 1999; Serial No: 09/376,630
- Also filed internationally
16. **Use of mCRP for delivery of materials into cells**
U.S. Continuation-in-part Application
Filed as coinvestigator with JA Radosevich and EE Diehl
Filed: 3 October 2001; Serial No: 09/971,100
Filed and Issued internationally various dates:1999-2002
17. **Use of mCRP to slow cell growth and to promote maturation of cells**
Filed as co-inventor with JA Radosevich
Filed 18 August 1999; Serial No: 09/376,398
Issued: 6,331,403 B1 18 Dec 2001
- Also filed internationally
18. **Use of mCRP to slow cell growth and to promote maturation of cells *Divisional application***
Filed as co-inventor with JA Radosevich
Filed 19 September 2001; Serial No: 09/957,280 ; US2002/037535A1;
Filed and Issued internationally various dates:1999-2002
19. **Use of mCRP to enhance immune responses**
US Application filed as co-inventor with JA Radosevich and EE Diehl
Filed 18 August 1999; Serial No. 09/376,628
Issued: 6,190,670 20 Feb 2001
- Also filed internationally
20. **Use of mCRP to enhance immune responses**
US Application filed as co-inventor with JA Radosevich and EE Diehl
Filed 18 August 1999; Serial No. 09/376,628
Issued: 6,280,743 28 Aug 2001
- Also filed internationally
21. **Use of mCRP to enhance immune responses**
Divisional application
Filed as co-inventor with JA Radosevich
Filed: 09 May 2000; Serial No. 09/567,954
Issued: 6.455.046 B1 24 Sept 2002

INVITED PRESENTATIONS

February 1978	Bradley University Peoria, IL
March 1980	Bradley University Peoria, IL
May 1981	Illinois Medical Technology Symposium, Chicago IL
May 1981	Rush University Pathobiochemistry Seminar Series Chicago, IL
October 1981	Loyola University Medical School Maywood, IL
October 1982	Rush Medical Center and University Grand Medical Rounds, Chicago, IL
January 1984	Lawrence University Appleton, WI
September 1984	National Institutes of Health Entrain Workshop Rocky Mountain National Laboratories Hamilton, MT
October 1984	The Society for Complex Carbohydrates Chicago, IL Annual National Meeting (300 + attendees)
February 1985	Northwestern University Feinberg School of Medicine Department of Molecular Biology Chicago, IL
March 1986	Rush Medical Center and University Medical Oncology Tumor Cell Biology Lecture Series Chicago, IL
November 1986	Rush Medical Center and University Biochemistry Department Pathobiochemistry Lecture Series Chicago, IL
November 1986	Midwest Connective Tissue Workshop. Chicago, IL
February 1987	Rush Medical Center and University Medical Oncology Tumor Cell Biology Lecture Series. Chicago, IL

February 1987	Northwestern University Feinberg School of Medicine Department of Molecular Biology, Chicago, IL
May 1989	The Children's Memorial Hospital Division of Immunology/Rheumatology, Chicago, IL
March 1990	Northwestern University Feinberg School of Medicine Section of Arthritis and Connective Tissue Diseases Multipurpose Arthritis Center, Chicago, IL
July 1990	Northwestern University Feinberg School of Medicine Section of Pulmonary Medicine. Chicago, IL
August 1990	International Congress on Membranes & Membrane Processes Chicago, IL
March 1991	Northwestern University Feinberg School of Medicine Department of Medicine - Section of Arthritis. Chicago, IL
August 1991	International Society of Artificial Organs Montreal, Ontario, Canada
April 1994	Bradley University. Peoria, IL
November 1994	Chicago Medical School (now Roselyn Franklin Medical School) North Chicago, IL
February 1996	Communitech Conference of Biotechnology. New York, NY
November 1996	Abbott Laboratories, Abbott Park, IL
November 1997	Franklin Research Group, Columbus, Ohio
June 1998	Rush Medical Center and University Department of Immunology/Microbiology, Chicago, IL
October 2000	University of Montreal Research Center Maisonnette-Rosemont Hospital Montreal, Ontario, Canada
May 2004	International Forum Nationwide Conference on China Hospital Management and Investment Beijing, China
November 2004	Abbott Laboratories Abbott Virology Group Abbott Park, IL

September 2008	HumanZyme, Inc, Chicago, IL
September 2011	Roosevelt University, College of Pharmacy, Schaumburg, IL
May 2011	Roosevelt University College of Pharmacy Faculty Research Seminar Series "The interaction of C-reactive protein with cell membranes and lipoproteins – Elucidation the biofunction of CRP"
April 2014	Roosevelt University College of Pharmacy Faculty Research Forum Seminar Series "High sensitivity CRP (hsCRP) testing : Medically useful or much ado about nothing?"
March 2015	apDia (advanced practical Diagnostics) Turnhout, Belgium "Perspectives on C-reactive protein as a diagnostic tool"
March 2015	Hasslet University Hasslet, Belgium "The evolving understanding of C-reactive protein structures and bioactivities"
March 2015	Roosevelt University, College of Pharmacy Faculty Research Forum Seminar Series "Snippets from the Symposium on <i>Psychoneuroimmunology</i>"
October 2015	Loyola University Stritch School of Medicine Joint Medical Grand Rounds -- Departments of Pathology, Psychiatry and Behavior Neurosciences "The evolving understanding of C-reactive protein structures and bioactivities. What does the diagnostic measurement of CRP teach us?"
December 2015	Roosevelt University - College of Pharmacy Department of Biopharmaceutical Sciences Faculty Research Forum "The evolving understanding of C-reactive protein structures and bioactivities. What does the diagnostic measurement of CRP teach us?"
February & March 2019	Roosevelt University - College of Pharmacy Pharmacy Faculty Research Rounds "Research for the Pharmacy Professional - An informal workshop to discuss processes and possibilities"

July 2019	Loyola University Stritch School of Medicine Medical Grand Rounds – Medical-Research Cooperative overviews <i>“C-reactive protein (CRP) - It’s way more than you think it is. Diagnostic and Therapeutic perspectives”</i>
September 2023	Roosevelt University - College of Pharmacy Pharmacy Faculty Research Rounds <i>“C-reactive protein (CRP). Diagnostic and Therapeutic perspectives”</i>
October 2025	Institute for Continued Learning - Roosevelt University <i>“The Drug Development Process”</i>

PROFESSIONAL MEMBERSHIPS – EDITORIAL BOARDS GRANT REVIEW/SITE VISIT TEAM MEMBER

Grant Review Feb 2025	National Science Foundation BIO/MCB (Division of Molecular and Cellular Biosciences) “Dynamics and Function of Lysine Acetoacetylation as a New Post-translational Modification”
---------------------------------	--

Societies:

1973 – 2018	American Chemical Society
Various times	American Association for the Advancement of Science
1980s-1990s	American Association of Immunologists
	Sigma Xi
	Chicago Heart Association
2010 – present	American Association of Colleges of Pharmacy

Editorial Boards:

December 2013 - present	Biophysics Reports Institute of Biophysics, Chinese Academy of Sciences 15 Datun Road, Chaoyang District Beijing 100101, China www.biophysics-reports.org .
November 2015-present	Review Editor Editorial Board Molecular Innate Immunity Frontiers in Immunology www.frontiersin.org
August 2020 – present	Cancers Topical Advisory Panel www.mdpi.com/journal/cancers

November 2022- present Associate Editor Frontiers Media SA, Avenue du Tribunal Fédéral 34,
1005 Lausanne, Switzerland (Frontiers) for Frontiers in Immunology.
Renewed June 2024

Provided Editorial Reviews for:

- Journal of Alzheimer's Disease
- Journal of Laboratory and Clinical Medicine
- Journal of Clinical Immunology
- Infection and Immunity
- Journal of Histochemistry and Cytochemistry
- Journal of Clinical Investigation
- Journal of Immunology
- Human Immunology
- Clinical Chemistry
- Scientific Reports
- Expert Review of Molecular Diagnostics
- MDPI Open Access Journals - Biology
- Pteridines
- Gene
- Frontiers in Immunology (Many reviews over Various subtopics)
- Practical Laboratory Medicine
- International Immunopharmacology
- Journal of Biological Chemistry
- Radiation Research
- Journal of Immunological Methods
- Artificial Organs
- Biotechniques
- Inflammation
- African Health Sciences
- Biophysics Reports
- Current Rheumatology Reviews
- Practical Laboratory Medicine
- Molecular Immunology
- PLOS ONE
- Diseases
- Cancers

Name included in published work as a reviewer:

- Pathak A, Agrawal A. 2019. Evolution of C-reactive protein. Front. Immunol.10:00943. <http://doi:10.3389/fimmu.2019.00943>
- Bloomfield M, Parackova Z, Cabelova T, Pospisilova I, Kabicek P, Houstkova H, Sediva A. 2019. Anti-IL6 autoantibodies in an infant with CRP-less septic shock Frontiers Immunology 10: 2629 <http://doi:10.3389/fimmu.2019.02629>
- Chen, Zu-Pei Liu, Zhen-Yu Yao, Yue-Xin Wu, Cheng-Sen Tong, Bin Cheng. 2020. Cellular folding determinants and conformational plasticity of native C-reactive protein Front. Immunol 11:00583. <http://doi:10.3389/fimmu.2020.00583>
- Pathak A, Singh SK, Thewke DP, Agrawal A. 2020. Conformationally altered C-reactive protein capable of binding to atherogenic lipoproteins reduces atherosclerosis. Frontiers Immunology. Front. Immunol. 11:01780. <http://doi:10.3389/fimmu.2020.01780>
- McFadyen JD, Dix C, Zeller J, Stevens H, Eisenhardt SU, Cheung KS, Nero TL, Morton CJ, Parker MW, Karlheinz Peter K. 2022. C-Reactive Protein, immunothrombosis and venous thromboembolism . Front. Immunol 13:1002652. <http://doi:10.3389/fimmu.2022.1002652>
- Molins B, Figueras-Roca M, Valero O, Llorenç V, Romero-Vázquez S, Sibila O, Adan A, Garcia-Vidal C, Soriano A. 2022. C-Reactive Protein Isoforms as Prognostic Markers of COVID-19 Severity. Front. Immunol. 13:1105343. <http://doi:10.3389/fimmu.2022.1105343>

- Dix C, Zeller J, Stevens H, Eisenhardt SU, Shing KSCT, Nero TL, Morton CJ, Parker MW, Peter K, McFadyen JD. 2022. C-reactive protein, immunothrombosis and venous thromboembolism. Front Immunol 13:1002652. <http://doi:10.3389/fimmu.2022.1002652>
- Hai-Hong Zhou, Yu-Long Tang, Tian-Hao Xu, Bin Cheng. 2024. C-reactive protein: structure, function, regulation, and role in clinical diseases . Front. Immunol 15:1425168. <http://doi:10.3389/fimmu.2024.1425168>
- Gao N, Yuan P, Tang Z-M, Lei J-G, Yang Z-R, Ahmed M, Wu Y, Haiyun L. 2024. Monomeric C-reactive protein is associated with severity and prognosis of decompensated hepatitis B cirrhosis . Front. Immunol. 15:1407768. <http://doi:10.3389/fimmu.2024.1407768>
- Manuscript INTIMP-D-24-07422R2. 2025. Unraveling APOE4: The Dual Role in CNS and Peripheral Inflammation in Alzheimer's Disease International Immunopharmacology.
- Others to be added

Served on a grant review/Site Visit team as a critical reviewer:

1979-1987	Rush Medical Center and University Committee on Research
1982	March of Dimes Birth Defects Foundation
1984	Ciba-Geigy Corporation
1989	State of Wisconsin Department of Development
2017	Roosevelt University Office of Research
2025	National Science Foundation Molecular and Cellular Biosciences

PRIMARY JOB RESPONSIBILITIES/COMMITTEE APPOINTMENTS

Roosevelt University – College/School of Pharmacy

- Chair – Research and Scholarly Endeavors

June 2017-present	• Promote and encourage personal and professional development of college staff • Promote and encourage creative research and extradidactic efforts of college students • Coordinate research efforts of college staff and students • Oversee research laboratory activities of staff and students • Oversee college and university administrative requirements of assigned staff
--------------------------	--

- Promote communication and cooperation amongst all college personnel
- Facilitate cooperative publications and presentations involving both clinical and basic research approaches utilized by college personnel
- Oversee Faculty Scholarship
- Promote communication and collaboration in creative research
- Promote dissemination of creative talents in publications and presentations
- Facilitate research programs
- Encourage and support efforts to acquire outside funding for research programs
- Establish and coordinate a Pharmacy Faculty Rounds Seminar Series
- Promote and encourage student research activities and participation
- Promote student scholarly endeavors

- **Professor (as of August 2021); Associate Professor of Biochemistry and Immunology (from 2010 to 2021)**

Oct 2010- present

- Course Director and sole lecturer of Foundational Sciences 1 (PHAR 503 – Biochemistry)
Lecturer – Foundational Sciences 4 (PHAR 608) – Clinical Microbiology and Immunology – Responsible for all Immunology topics
- Course Director of Biochemistry 2 (PHAR511)
- Course Director Clinical Microbiology and Immunology (PHAR512)
- Course Director – Independent Research in Biopharmaceutical Drug Discovery (PHAR 560)
- Course Director – Advanced Independent Research in Biopharmaceutical Drug Discovery (PHAR 573)
- Course Director – The Drug Development Process (Phar 557)
- Lecturer Nutrition – Biochemistry of Metabolism (Phar 540)
- Lecturer Integrated Sequence VII – Musculoskeletal and Immune System Director of Biochemistry 1 (PHAR510)
- Course Director – Biotherapeutic Drugs - Biochemical and Immunological Mechanism of Action (PHAR 654)
- Organizer and Chair – Biopharmaceutical Sciences Faculty Research Forum (2012-2016)
- Faculty Search Committee – Biopharmaceutical Sciences (BPS) Department and Clinical and Administrative Sciences (CAS) Departments
- Curriculum Committee: 2013, 2014, 2015, 2016, 2017
- Admissions Committee: 2011, 2012, 2013, 2014, 2015, 2016, 2017
- Student Scholarship Committee 2015-2018
- Chair of the Scholarship Committee – 2016-2018
- Chair – Affiliate Faculty Appointment Committee 2011-2012
- Self-Study Board for Accreditation – Primary focus on the Subcommittee for Standards for Faculty and Staff
- Responsible for establishing Independent Research Laboratories for innovative research and teaching

- Member of committee to establish Doctor of Philosophy training programs in the College of Pharmacy of Roosevelt University
- Search Committee for University - wide Position of Associate Provost of Graduate Studies and Research – Spring 2012
- Chair – Foundational Course Review Committee (Sept 2022-present)

Acphazin, Inc

Founder, President and Chief Science Officer

2007-present

- Maintained intellectual property
- Pursued development opportunities
- Published and nurtured advances with international collaborations

Angiogen, Inc

Consultant – for Cancer Therapeutics

2006-2008

- Provided expertise on options and procurement of key elements in an Anti-angiogenic cocktail for human clinical trials in cancer.
- Summarized initial human trials performed with early cocktail mixtures.
- Updated preliminary information and background for investigator's brochure.
- Wrote a complete human protocol for follow-up human trials

NextEra Therapeutics, Inc

Biologic Drug development – Immune stimulation and control

1998-2002

- Board of Directors (1998-2000)
- Scientific Founder
- Vice President and Chief Scientific Officer
- Key Employee – Key Man Life Insurance policy with Company as beneficiary.
- Responsible for directing and managing scientific efforts of the companies. primary focused therapeutic developments.
- Responsible for raising operating capital of \$1,3500,000.
- Responsible for representing company's science, clinical programs, and product development plans to investors and the investment community.
- Responsible for establishing, maintaining and expanding the Company's proprietary patent base.
- Awarded a Phase I NIH SBIR – Innate Immunity, C-reactive protein and Wound Healing (work in collaboration with Ohio State University) (\$107,000)
- Established contract arrangements for large-scale, GMP-level production of recombinant protein, including documentation, Master Drug File, and validation issues.
- Responsible for advancing Company's interests in clinical and strategic opportunities in Europe and Japan.
- Expanded company's product portfolio.
- Established and expanded on collaborative scientific relationships.
- Responsible for scientific staff and laboratory resources

ImmvaRx, Inc

Consultant – for Cancer Vaccines

- 1998-1999**
- Consultant for the development of peptide-based vaccines for cancer.
 - Consultant for the development of human friendly adjuvants

Immtech International, Inc

Program Manager – Antimicrobial drug development

- 1996-2003**
- Coordinated scientific and technical efforts of dicationic drug discovery and development programs.

Director of Biotherapeutics

- 2000-2002**
- Coordinated scientific and technical efforts of protein-based products licensed to the company.

Vice President Research and Chief Scientific Officer

- 1996-2000**
- Key scientist/management for Immtech International Inc. Initial Public Offering – April 1999 (raised \$11,500,000).
 - Directed and managed scientific efforts of the company's primary focused therapeutic developments.
 - Coordinated scientific and technical efforts in licensing anti-infection pharmaceutical compounds from the University of North Carolina Research Consortium (including Auburn, Duke and Georgia State Universities)
 - Awarded a Phase II NIH SBIR Grant with Dr. Tidwell and Dr. Hall (North Carolina) – New Broad-Spectrum Drugs for opportunistic infections (\$796,638).
 - Co-investigator of a Phase II NIH SBIR Grant with Dr. JL Allen as PI – Novel prodrugs for the treatment of opportunistic infections (\$790,000)
 - Awarded a Phase I NIH STTR Grant with D. Boykin (Georgia State) and D. Kyle (Walter Reed) - Dicationic prodrugs against tropical infections (\$100,000).
 - Awarded a Phase I NIH STTR Grant with H. Reisner (U North Carolina at Chapel Hill) - Immunoassays of pentamidine-like (dicationic) drugs (\$100,000).
 - Key company employee. Key-man life insurance with Company as beneficiary.
 - Responsible for establishing, maintaining and expanding the Company's proprietary patent base.
 - Responsible for raising investment capital with both private investors, venture capitalists, institutional investors, and leading up to an initial public offering. Total amount is in excess of \$7,500,000.
 - Coordinated Company's efforts to enter into expanded human clinical trials with both pharmaceutical and biological products including physician/institutional relationships.
 - Established and expanded on collaborative scientific relationships.

- Established contract arrangements for large-scale, GMP-level production of recombinant protein and pharmaceutical compounds.
- Established and advanced strategic partnering relationships with ProlImmune, Ltd. of Hong Kong and Nottingham, England.
- Responsible for advancing Company's interests in clinical and strategic opportunities in Europe and Japan.
- Expanded company's product portfolio.

Chief Scientific Officer – Director of Immunology

- 1992-1995**
- Directed and managed all aspects of the company's primary focused development.
 - Responsible for representing scientific efforts and accomplishments in raising operating capital in excess of \$5-million
 - Coordinated efforts to cost-effectively produce and manufacture recombinant protein suitable for human clinical trials.
 - Successfully organized and documented all regulatory information which led to the approval and realization of two human clinical trials.
 - Represented company's research and development efforts in partnering presentations for both domestic and world-wide markets
 - Have filed and defended both domestic and international patent applications covering eight discovery indications.
 - Managed laboratory and office facilities, including on site construction and operation of Good Manufacturing Practice clean room facilities.
 - Supervised a staff of up to 12.

Director of Immunology; Key Scientist; Program Manager

- 1990-1992**
- Coordinated scientific and technical efforts of protein-based products licensed to the company.
 - Directed and managed all aspects of the company's primary focused development as a key company employee.
 - Discovered and established medical relevancy for a novel form of a human protein with immunomodulating activities.
 - Established and implemented a strategy for drug development including procurement of materials and recombinant protein.
 - Awarded a National Institutes of Health-SBIR Grant.
 - Awarded the State of Wisconsin Department of Development Innovation and Research Award.
 - Established & managed the company's 1st independent research & office facility.
 - Established consultative arrangements for efficient procurement of test specimens and samples.
 - Designed protocols, prepared test specimens and arranged for pre-clinical testing by outside collaborators or contract laboratories.
 - Supervised a research team and was responsible for markedly improving overall laboratory efficiency and productivity.

- Managed daily accounting matters.
- Contributed significantly to company's ability to attract in excess of \$ 1 million in private placement and partnership funds.
- Have filed both domestic and international patent applications.

Program Director; Senior Research Scientist

- 1988-1990**
- Coordinated scientific and technical efforts of protein-based products licensed to the company.
 - Directed and managed all aspects of the company's primary focused developments
 - Discovered and established medical relevancy for a novel form of a human protein with immunomodulating activities

Northwestern University Medical School **Adjunct Associate Professor**

- 1989-1995**
- Consulting responsibilities as needed.
 - Teaching responsibilities as needed

Rush Medical Center and University

- 1982-1987**
- University Committee on Research (Reviewed and Awarded Basic Research Starter Grants)
 - Consultant, Office of Consolidated Laboratory Services (Clinical Immunology/Immunochemistry)
 - University Task Force on Recruiting
 - University Research Symposium Planning Committee
 - University Task Force on Library Policies
 - Self-Study Steering Committee for the North Central Association of Colleges and schools Reaccreditation of Rush University
 - Search Committee for the Chairman of the Department of Communication

Rush Graduate College

- 1978-1987**
- Course Director: Structure and Immunobiology of Membranes
 - Selected lectures: Biology of Membranes
 - Course Director: Molecular Immunology
 - Selected lectures: Complement
 - Head, Admissions Committee - Graduate Division of Immunology
 - Graduate Advisory Committee - Graduate Division of Immunology
 - Graduate College Task Force on Recruiting
 - Graduate Program Director - Graduate Division of Immunology
 - Dissertation Co-advisor, **Nancy L. Samberg, PhD** -Degree Awarded Nov 1987
 - Force Dissertation Co-advisor, **Ruthann Rees, PhD** -Degree Awarded May 1990

- Dissertation Co-advisor, **Elton B. Chu, PhD**-Degree Awarded December 1991
- Dissertation Advisor, **Tod R. Fairbanks, PhD**-Degree Awarded April 1984
- Task on Quality Education within the Graduate College

Rush Medical College

- 1978-1987**
- Selected Lectures, Basic and Clinical Immunology
 - Assistant Course Director-Basic and Clinical Immunology
 - Medical School Admissions Committee
 - Medical College Committee on Committees & Faculty Committee on Dialog
 - Selected Lectures, Medical Microbiology
 - Committee on Senior Faculty Appointments and Promotions

Department of Immunology/Microbiology

- 1978-1987**
- Member, Graduate Division of Immunology faculty
 - Departmental Advisory Committee
 - Member, Allergy/Clinical Immunology faculty
 - Assistant to the Chairman

MOST VALUED US & INTERNATIONAL COLLABORATORS/RESEARCH ASSOCIATES

Professor Janos G. Filep, MD	Research Center - Maisonneuve-Rosemont Hospital University of Montreal Montreal Quebec, Canada H1T 2M4 janos.g.filep@umontreal.ca
Professor Yi Wu, PhD	Key Laboratory of Precision Medicine to Pediatric Diseases of Shaanxi Province, the Affiliated Children's Hospital, Xi'an Jiaotong University, Xi'an, China; Tel/Fax: +86-13893667930; Email: wuyi_med@mail.xjtu.edu.cn Lanzhou University Department of Biology Institute of Biophysics Laboratory of Biomembranes Lanzhou, China 730000 wuy@lzu.edu.cn
Professor Karlheinz Peter, MD PhD	Baker Heart Research Institute Head, Center of Thrombosis and Myocardial infarction Melbourne (Pahran) Australia Karlheinz.Peter@baker.edu.au
Professor Mark Slevin PhD, FAHA, FIBMS, FRCPATH	Head of Genetics/Cell and Molecular Biology Professor of Cell Pathology, School of Healthcare Science, Manchester Metropolitan University

Editor-In-Chief, Vascular Cell and Editor of "Therapeutic
Angiogenesis for vascular Disease
Editor-In-Chief, Vascular Cell and Senior Associate Editor of
Brain Pathology
M.A.Slevin@mmu.ac.uk

Christopher Sjöwall, MD PhD

Senior Lecturer/Associate Professor
Department of Clinical & Experimental Medicine
Rheumatology/Division of Neuro & Inflammation Sciences
Autoimmunity & Immune-Regulation (AIR)
Campus US, Linköping University
SE-581 85 Linköping, SWEDEN
christopher.sjowall@liu.se

Wendy Wei Qiao Qiu, MD PhD

Professor of Psychiatry and Pharmacology
Boston University
Department of Pharmacology & Experimental Therapeutics
Boston, MA
wqiu67@bu.edu

**Anniken Jørlo Fuglestad, MD,
PhD**

Medical Doctor at Sørlandet HospitalCenter for Cancer
Treatment, Sorlandet Hospital, Kristiansand, Norway

Department of Oncology, Akershus University Hospital,
Nordbyhagen, Norway a.j.fuglestad@studmed.uio.no